

Index of subjects Volume 7 (1996)

- A**
- α -interferon**
as a treatment for patients with metastatic colorectal carcinoma 575
as a treatment for patients with metstatic carcinoid and malignant endocrine pancreatic tumours (Short report) 208
as a treatment for patients with neuroendocrine gastrointestinal tumours (Review) 459
in combination therapy with 5-fluorouracil (Short report) 208, 575
- acute aortic thrombosis**
in patients with small-cell lung carcinoma (Letter to the editor) 321
- acute lymphoblastic leukemia**
meta-analysis and prospective meta analysis in clinical research (Arena) 1009
monitoring L-asparagine depletion in plasma and cerebro-spinal fluid 725
secondary malignancies (Letter to the editor) 322
successful treatment (Letter to the editor) 322
- acute myelogenous leukemia**
probability of long-term disease-free survival 933
- adenocarcinoma**
of the esophagus or esophago-gastric junction area (Short report) 533
- adenoid cystic carcinoma**
in head and neck (Short report) 867
treatment with mitoxantrone (Short report) 867
- ADEPT**
used in cancer drug therapy (Special article) 445
- adjuvant chemo-tamoxifen therapy**
as a treatment for patients with early breast cancer 239
risk of new primaries 239
- adjuvant chemotherapy**
as a treatment for patients with breast cancer (Short report) 745
as a treatment for patients with early breast cancer 239
long-term results in stage I and II Hodgkin's disease 145
risk of new primaries 239
- adjuvant surgery**
as a treatment for patients with small-cell lung cancer 303
- adjuvant systemic treatment**
in breast cancer (Editorial) 221
- adjuvant tamoxifen**
as a treatment for patients with early breast cancer 239
risk of new primaries 239
- adjuvant therapy**
as a treatment for patients with breast cancer 245
as a treatment for patients with colon cancer (Short report) 412
effect of occurrences in second malignancies 245
multifocal leukoencephalopathy (Short report) 412
- adjuvant treatment**
in node-negative and estrogen receptor-negative breast cancer 481
- adoptive cellular therapy**
as a treatment for patients with metastatic renal cell cancer (Review) 887
- advanced breast cancer**
mobilisation kinetics of primitive haemopoietic cells following G-CSF 1051
treatment with doxorubicin and paclitaxel 687
treatment with intravenous infusion of 5-fluorouracil 807
- advanced colorectal carcinoma**
factors influencing response rates (Arena) 901
treatment with oxaliplatin (Short report) 95
- advanced multiple myeloma**
use of oral idarubicin and prednisone (Letter to the editor) 537
- advanced non-small-cell lung cancer**
use of radiotherapy preceded by high-dose chemotherapy versus high-dose radiotherapy 139
- advanced ovarian cancer**
single agent activity of oxaliplatin 1065
- advanced pancreatic adenocarcinoma**
treatment with 5-fluorouracil, leucovorin and cisplatin 173
- advanced salivary gland carcinoma**
treatment with chemotherapy (Short report) 640
treatment according to CAP regimen (Short report) 640
- advanced squamous cell carcinoma of head and neck**
phase II trial (Letter to the editor) 539
treatment with 13-cis retinoic acid plus interferon- α (Letter to the editor) 539
- advanced stages**
of Hodgkin's disease (Review) S4: 99
- aetiology**
in Hodgkin's disease (Review) S4: 5
- AIDS**
related to non-Hodgkin's lymphoma 1029
- akathisia**
associated with prochlorperazine as an antiemetic (Editorial) 103
- allogeneic blood progenitor cells**
transplantation of (Review) S2: 41
- allogeneic bone marrow transplantation**
schedules in high-dose chemotherapy 83
- allogeneic transplantation**
of cord blood (Review) S2: 47
of Ph1-negative blood progenitor cells in chronic myelogenous leukaemia (Review) S2: 19
- American perspective**
on clinical benefit (Editorial) 335
- AML**
cytokine production 397
treatment with interleukin 10 397
- anaplastic**
carcinoma of the thyroid (Clinical case) 739
- angiogenesis**
bFGF and VEGF 843
- angiogenesis inhibitors**
clinical studies (Editorial) 441
phase I study 491
tegogalan sodium 491
- animal study**
stem cells in mice (Review) S2: 15
- antibodies**
as anticancer agents (Special article) 445
- anticancer chemotherapy**
as a treatment for patients with breast cancer 165

- multicentre phase II study 165
- antineoplastic agents
 - use in the therapy of HIV-related non-Hodgkin's lymphoma 1029
- antiprogestins
 - in the human breast cell line T-47D 391
 - induction of TGF-beta 391
- antiretroviral therapy
 - use in HIV-related non-Hodgkin's lymphoma 1029
- antithrombin III
 - interaction between HRT and tamoxifen 671
- application schedules
 - in patients with bone marrow transplantation 83
- aPTT
 - pentosan 939
- aromatase inhibitors
 - as a treatment of patients with advanced breast cancer 471
 - as a treatment of patients with breast cancer (Short report) 99
 - new generation of (Editorial) 433
- arthralgia
 - in a patient with metastatic carcinoma of the breast (Letter to the editor) 756
- attitudes
 - toward euthanasia 907
- autograft
 - hematopoietic recovery 719
- autologous blood stem cell transplantation
 - for patients with chronic lymphocytic leukemia 373
 - long-term survival 373
- autologous bone marrow transplantation
 - in patients with acute myeloid leukemia 933
 - in patients with breast cancer (Review) S2: 31
- autologous transplantation
 - haemopoietic stem cells (Review) S2: 5
 - of Ph1-negative blood progenitor cells (Review) S2: 19
 - in patients with chronic myelogenous leukaemia (Review) S2: 19
- B**
- B-cell lymphoma
 - new classification (Review) S6: 3
 - classification and therapeutic implications (Review) S6: 35
- B-CLL
 - evolution into chronic lymphocytic leukaemia (Clinical case) 953
- bax
 - in relation to Bcl-2 in breast cancer (Rapid publication) 129
- bcl-1
 - involvement of the CCND1 gene 251
- bcl-2
 - clinical significance for patients with diffuse large B-cell lymphomas 1023
 - expression of Bax in breast cancer (Rapid publication) 129
- bcl-2 rearrangement
 - detection of cells (Rapid publication) 793
 - in patients with non-Hodgkin's lymphoma (Rapid publication) 793
- Ber-H2/saporin
 - for clinical use in Hodgkin's disease (Review) S4: 135
- bilharziasis
 - treatment with combination therapy (Short report) 751
- biliary cancer
 - and the quality of life 593
- survival improvement in patients 593
- biochemical modulation
 - as a treatment for patients with advanced colorectal cancer 581
 - of 5-FU with leucovorin 581
- biochemotherapy
 - treatment of patients with metastatic melanoma 827
- biological markers
 - diagnostic and prognostic value 607
 - in neuroblastoma 607
- biology
 - report on the workshop of the Third International Symposium on Hodgkin's Lymphoma in Cologne 1995 (Symposium article) S4: 45
- bioreductives
 - as a new approach in cancer chemotherapy (Special article) 445
- biotherapy
 - in combination with chemotherapy 827
 - treatment of patients with metastatic melanoma 827
- bispecific antibodies
 - treatment of Hodgkin's disease (Review) S4: 143
- bladder cancer
 - treatment with combination chemotherapy (Short report) 751
- bone marrow
 - analysis of prognostic factors associated with hematopoietic recovery 719
 - autotransplant of progenitor cells 719
 - study of haemopoietic stem cells (Review) S2: 5
- bone marrow stromal cultures
 - as a therapy for patients with advanced breast cancer 1051
- bone marrow transplantation
 - and high-dose chemotherapy 151
 - as a treatment in patients with Hodgkin's disease 151
 - use in therapy of low-grade non-Hodgkin's lymphomas (Review) S6: 13
- bone metastases
 - treatment with prednisone (Letter to the editor) 640
- bone mineral density
 - effect of tamoxifen and hormone replacement therapy 671
- bone sarcomas
 - treatment with neoadjuvant chemotherapy (Short report) 864
- breast cancer
 - antiprogestins 391
 - carcinomatous meningitis (Review) 773
 - detection of 619
 - dose-intensive chemotherapy for 35
 - effects of adjuvant systemic treatment (Editorial) 221
 - effects of fadrozole versus tamoxifen 471
 - effects of prednisone combined with CMF 245
 - efficacy and safety of docetaxel as first-line treatment 165
 - expression of Bax in relation to Bcl-2 (Rapid publication) 129
 - hormonal replacement therapy 655
 - induction of TGF-beta 391
 - locally advanced 165
 - metastatic 165, 465, 487
 - node-negative 481
 - phase II trial (Short report) 857
 - pretreated 55
 - psychological distress (Letter to the editor) 977
 - role of maspin gene 619
 - treatment with adjuvant chemotherapy 239, 745 (Short report)
 - treatment with adjuvant therapy 245, 695, 977 (Letter to the editor)

- treatment with CMF-inf (Short report) 409
 treatment with 8-chloroadenosine 3',5' monophosphate 291
 treatment with paclitaxel and vinorelbine (Short report) 857
 treatment with tamoxifen 239
 use of aromatase inhibitors in treatment of patients with (Short report) 99
breast neoplasms
 dose intensification (Review) S2: 31
 peripheral blood progenitor cells (Review) S2: 11
- C**
- CA 125
 progression of ovarian carcinoma 361
cancer
 CARES-SF 381
 chemotherapy (Special article) 445
 elderly patients 677
 euthanasia 907
 incidence and mortality 497
 palliative and supportive care (Arena) 135
 patient perceptions of the effects of chemotherapy 189
 quality of life 381
 research (Editorial) 439
 treatment (Editorial) 657
 treatment with pentosan 939
 use of hypnotics (Short report) 855
cancer drug development
 phase I trials (Commentary) 567
cancer pain
 use of methadone 613
cancer therapy
 use of the nuclear matrix (Review) 659
cancer vaccines
 immune monitoring of (Commentary) 667
 peptide-based (Review) 339
 recognition of tumour-associated antigens (Review) 339
CAP regimen
 as a treatment for patients with advanced salivary gland carcinoma (Short report) 640
carboplatin
 as a treatment for patients with locally advanced carcinoma of the cervix 511
 as a treatment for patients with good-risk metastatic non-seminomatous germ cell tumours 1015
 as a treatment for patients with small-cell lung cancer 365
 comparison with cisplatin 365
 in combination chemotherapy of non-seminomatous germ cell tumours (Editorial) 989
 in combination with teniposide and vincristine 365
carcinoid
 treatment with a combination of interferon- α -2a and 5-fluorouracil (Short report) 208
carcinoïds
 as part of the neuroendocrine gastrointestinal tumours (Review) 453
carcinomatous meningitis
 in solid tumours (Review) 773
cardiac sequelae
 after treatment for Hodgkin's disease 257
 increased risks in females 257
- cardiotoxicity
 of 5-fluorouracil 731
 of combined doxorubicin and paclitaxel in advanced breast cancer 687
CARES-SF
 and the quality of life 381
 validity and reliability 381
causes of death
 of patients with Hodgkin's disease (Review) S4: 115
CCND1
 in hairy cell leukemia 251
cDNA libraries
 its role for analysis of Hodgkin's disease (Review) S4: 35
CD30
 ligand interaction in Hodgkin's lymphoma (Symposium article) S4: 45
CD34+ blood cells
 allogeneic transplantation (Review) S2: 41
 transduction of (Review) S2: 53
CD34+ cells
 loss from (Review) S2: 47
 positive selection of ex vivo expansion of (Review) S2: 11
cell culture model
 influence of 5-FU 731
cell cycle regulation
 fundamental research on (Commentary) 343
cell transplantation
 as a treatment for patients with inoperable relapse of nuchal liposarcoma (Letter to the editor) 871
cervical cancer
 treatment with concurrent chemo- and radiotherapy 511
CGS 16949A
 treatment in women with advanced breast cancer 471
 versus tamoxifen 471
challenges
 for the future in ovarian cancer research 9
chemoradiotherapy
 treatment for patients with small-cell lung cancer 303
chemoprevention
 instead of cancer chemotherapy (Special article) 445
chemotherapy
 alone in treatment of early stage Hodgkin's disease (Review) S4: 85
 and G-CSF for patients with advanced breast cancer 1051
 as a treatment
 for elderly patients (Short report) 966
 for patients with
 advanced biliary tract carcinoma (Short report) 751
 advanced breast cancer 807
 advanced colorectal cancer (Arena) 901, (Short report) 961
 advanced endometrial cancer (Short report) 861
 advanced pancreatic cancer 593
 advanced salivary gland carcinoma (Short report) 640
 advanced testicular choriocarcinoma (Letter to the editor) 536
 biliary cancer 593, (Letter to the editor) 644
 bone sarcomas (Short report) 864
 breast cancer 35, S2: 31 (Review)
 carcinoma of the thyroid (Clinical case) 739
 cervical cancer 511
 chronic myelogenous leukaemia (Review) S2: 19
 esophageal carcinoma 353

- 5-FU-refractory pancreas cancer (Rapid publication) 347
 head and neck cancer (Review) 15
 Hodgkin's disease 257, (Special article) 555, (Review) S4: 109,
 (Clinical case) 1071
 metastatic melanoma 827
 non-Hodgkin's lymphomas (Short report) 966, S6: 13 (Review)
 non-seminomatous germ cell tumours 1015, (Editorial) 989
 non-small-lung cancer 311, (Short report) 414, 517, (Short report)
 637, 821
 ovarian carcinoma 65, 705
 solid tumours (Review) S2: 23
 testicular cancer 31
 combined with radiotherapy 919
 CPT-11 dosage 837
 for bulky or advanced Hodgkin's disease (Review) S4: 105
 haemopoietic stem cells (Review) S2: 5
 historical control studies 355
 improvement of quality of life 593
 in advanced Hodgkin's disease (Review) S4: 95
 in combination with biotherapy 827
 low-dose continuous intravenous infusion of 5-fluorouracil 807
 low-dose cisplatin- or non-cisplatin 505
 neoadjuvant (Short report) 864, (Letter to the editor) 871
 occurrence of cardiopulmonary sequelae 257
 optimum anti-emetic therapy 277
 patient perceptions of side effects 189
 peripheral blood progenitor cell transplantation (Introduction) S2: 1
 phase I study (Short report) 311, 314
 phase II study (Rapid publication) 347, (Short report) 637, (Short report)
 861
 phase III randomised trial 821
 prolongation of survival 593
 pulmonary toxicity (Short report) 973
 purging of peripheral blood progenitor cells (Review) S2: 11
 randomized trials 355
 childhood
 present and future strategies of Hodgkin's lymphoma's treatment (Review)
 S4: 73
 cholesterol
 interaction between HRT and tamoxifen 671
 choriocarcinoma
 diagnosis of residual disease (Short report) 416
 diagnosis of tumour emboli (Short report) 416
 positron emission tomography (Short report) 416
 chromogranin A
 in neuroendocrine gastrointestinal tumours (Review) 454
 chronic lymphocytic leukemia (CLL)
 long-term survival 373
 purine analogs (Review) S6: 27
 treatment with 2-CdA-therapy 373
 chronic myelogenous leukaemia
 mobilization/transplantation of Ph1-negative blood progenitor cells (Review)
 S2: 19
 CHVmP
 as a treatment for patients with non-Hodgkin's lymphomas 925
 cisplatin
 as a treatment for patients with
 advanced endometrial cancer (Short report) 861
 advanced pancreatic adenocarcinoma 173
 good-risk metastatic non-seminomatous germ cell tumours 1015
 non-small cell lung cancer and malignant melanoma (Short report)
 1080
 ovarian cancer 65, 1077 (Short report)
 small-cell lung cancer 365, 747 (Short report)
 compared to carboplatin 365
 in combination with teniposide and vincristine 365
 induction of delayed emesis 945
 phase III study in non-small-cell lung cancer 517
 cisplatin resistance
 in testicular cancer 31
 cladribine
 treatment for patients with non-Hodgkin's lymphoma (Rapid publication)
 793
 classification systems
 of mantle-cell lymphoma (Review) S6: 35
 clinical
 research of ovarian cancer 9
 studies with angiogenesis (Editorial) 441
 trials in Hodgkin's disease (Review) S4: 109, 127
 clinical benefit
 an American perspective (Editorial) 335
 an European perspective (Editorial) 333
 for patients with pancreatic cancer (Rapid publication) 347
 phase II trial of gemcitabine (Rapid publication) 347
 Clinical cases
 anaplastic
 carcinoma of the thyroid 739
 B-CLL
 evolution into chronic lymphocytic leukaemia 953
 chemotherapy
 as a treatment for patients with carcinoma of the thyroid 739
 as a treatment for patients with Hodgkin's disease 1071
 clonality
 in B-cell lymphoma 953
 corticosteroids
 in granulosa cell tumour of the ovary 521
 follicular lymphoma
 histological transformation 849
 granulosa cell tumour
 of the ovary 521
 Hodgkin's disease
 complications by second cancers 405
 meningeal localization in a patient 1071
 immunogenotype
 in lymphocytic leukemia 953
 immunophenotype
 in lymphocytic leukemia 953
 leukaemia
 complicating Hodgkin's disease 405
 lung cancer
 role of surgery in small-cell 303
 lymphoma
 clonal analysis 953
 evolution into lymphocytic leukemia 953
 meningeal lymphoma
 in patients with Hodgkin's disease 1071

- prognosis
 for patients with follicular lymphoma 849
- radiation
 therapy for patients with anaplastic carcinoma of the thyroid 739
- radiotherapy
 as a treatment for patients with Hodgkin's disease 1071
- second cancers
 in Hodgkin's disease 405
- leukemia 405
- small-cell lung cancer
 the role of surgery 303
- thyroid cancer
 anaplastic 739
- transformation
 of indolent lymphoma 849
- treatment
 of patients with follicular lymphoma 849
 of patients with granulosa cell tumour of the ovary 521
- tumour lysis syndrome
 review of literature 631
- clonal evolution
 and tumour heterogeneity (Review) 121
- clonal heterogeneity
 analysis of Hodgkin's disease (Review) S4: 35
- clonality
 and tumour heterogeneity (Review) 121
 in B-cell lymphoma (Clinical case) 953
 of Hodgkin and Reed-Sternberg cells (Review) S4: 11
- clubbing
 in a patient with metastatic carcinoma of the breast (Letter to the editor) 756
- CMF
 as a treatment for patients with breast cancer (Short report) 409
 combined with adjuvant prednisone 245
 effects of treatment in patients with breast cancer 245
 effects on patterns of relapse 245
 infusional (Short report) 409
- cognitive function
 effect of hypnotics discontinuation (Short report) 855
- colon cancer
 multifocal leukoencephalopathy (Short report) 412
 treatment with levamisole adjuvant therapy (Short report) 412
- colony stimulating factors
 treatment of patients with HIV-related non-Hodgkin's lymphomas (Arena) 233
- colorectal cancer
 magnetic resonance spectroscopy 47
 phase I study (Short report) 317
 prolonged continuous hepatic artery infusion with interleukin-2 (Short report) 317
- TCNU (Letter to the editor) 211
- treatment with bFGF and VEGF 843
- treatment with 5-fluorouracil 41, (Editorial) 531
- treatment with 5-fluorouracil plus α -interferon 575
- unresectable liver metastases (Short report) 317
- colorectal cancer (advanced)
 phase II trial 581
 randomised trial (Short report) 961
- treatment with 5-fluorouracil plus oral leucovorin 581, (Short report) 961
- treatment with tomudex 179, (Short report) 961
- combined chemotherapy-radiotherapy
 as a treatment for patients with localized low-grade lymphoma 157
- combined modality therapy
 as a treatment for patients with bulky or advanced Hodgkin's disease (Review) S4: 105
- as a treatment for patients with Hodgkin's disease (Special article) 555
- as a treatment for patients with non-Hodgkin's disease 925
- as a treatment for patients with stage I, II MALT lymphoma and mantle cell lymphoma (Letter to the editor) 211
- complete remission
 after 2-CdA therapy 373
 in patients with CLL 373
- continuous infusion
 for patients with advanced colorectal cancer 581
 of 5-HU plus leucovorin 581
- cord blood
 as an alternative source of haemopoietic stem cells (Review) S2: 47
 in peripheral blood progenitor cell transplantation (Introduction) S2: 1
- corticosteroids
 in granulosa cell tumour of the ovary (Clinical case) 521
- counseling
 of genetic testing (Special article) 891
- CPT-11
 dosage schedules 837
- cromoglycate
 docetaxel rechallenge (Editorial) 104
- current strategies
 in treatment of Hodgkin's disease (Review) S4: 109
- cyclin D1
 identification of molecular alterations (Editorial) 222
- involvement in hairy cell leukemia 251
- clinical significance of 695
- cyclin-dependent kinase
 fundamental research (Commentary) 343
- cyclin-dependent kinase inhibitors
 fundamental research (Commentary) 343
- cyclins
 fundamental research (Commentary) 343
- cyclophosphamide
 delayed emesis induction 71
- cytogenetics
 in Hodgkin's disease (Review) S4: 49
- cytokines
 haemopoietic stem cells (Review) S2: 47
 in peripheral blood progenitor cell transplantation (Introduction) S2: 1
- production in adult mice (Review) S2: 15
- production in patients with AML 397
- purging of peripheral blood progenitor cells (Review) S2: 11
- treatment with interleukin-10 397
- cytolytic T-lymphocytes
 perspectives for peptide-based vaccines (Review) 339
- recognition of tumour-associated antigens (Review) 339
- D**
- DAM486IL-2
 clinical use in Hodgkin's disease (Review) S4: 135

- delayed emesis
 caused by emetogenic chemotherapy 71
 cisplatin-induced 945
 oral dexamethasone in prophylaxis 71
- delayed nausea
 cisplatin-induced 945
- detoxification
 role of the LRP protein 625
- dexamethasone
 compared to placebos and ondansetron 945
 for control of cisplatin-induced delayed emesis 945
 prevention of hypersensitive reactions to paclitaxel (Letter to the editor) 978
- emetogenic chemotherapy 71
- developmental therapeutics
 in the treatment of patients with germ-cell tumours (Review) 997
- diarrhoea
 comparing drugs for the prevention of 587
- disseminating disease
 expression of tyrosinase 297
 reverse transcriptase-polymerase chain reaction 297
 through peripheral blood 297
- DNA primase
 in cancer therapy (Review) 659
- DNA topoisomerase I inhibitor
 in CPT-11 837
- docetaxel
 efficacy and safety as a treatment for patients with advanced breast cancer 165
 rechallenge with cromoglycate (Editorial) 104
- dosage schedules
 of CPT-11 837
- dose
 phase I trials (Commentary) 567
- dose escalation
 current clinical trials in Hodgkin's disease (Review) S4: 109
 of high-dose CDE with G-CSF for poor-risk non-Hodgkin's lymphoma 1037
- dose-finding
 study in chemotherapy 505
 of tropisetron 505
- dose intensity
 in chemotherapy for patients with adult solid tumours (Review) S2: 23
 in chemotherapy for patients with breast cancer 35, (Review) S2: 31
 in primary chemotherapy for patients with ovarian carcinoma 705
 in therapy for patients with colorectal cancer 41
 peripheral blood progenitor cells (Review) S2: 11
- dose-limiting toxicity
 phase I trials (Commentary) 567
- dose-response
 in patients with breast cancer (Review) S2: 31
 relationship in patients with advanced Hodgkin's disease (Review) S4: 95
- doxorubicin
 in advanced breast cancer 687
- drug therapy
 and hematopoietic rescue 151
- as a treatment for patients with Hodgkin's disease 151
- E**
- early breast cancer
 treatment with adjuvant chemotherapy 239
 treatment with tamoxifen 239
- early stages
 of Hodgkin's disease (Review) S4: 79, 85, 91
- EBV-specific immunity
 by EBV-induced modulation of cytokine expression pattern of HRS cells (Review) S4: 11
- 8-chloroadenosine 3',5'-monophosphate (8-Cl-cAMP)
 metabolism 291
 pharmacokinetics 291
 treatment for patients with breast cancer 291
 tumour disposition 291
- elderly patients
 age specific differences 677
 diagnostics and treatment 677
 effects of granulocyte colony-stimulating factor administration (Short report) 966
 treatment with a pirarubicin-combination chemotherapy regimen (Short report) 966
- emesis
 cisplatin induced 277
 comparing drugs for the prevention of nausea 587
 in patients undergoing fractionated radiotherapy 587
 optimum therapy 277
- end results
 of the treatment of patients with Hodgkin's disease (Special article) 555
- endocrine pancreatic tumours
 treatment with chemotherapy (Review) 453
- endocrine therapy
 as a treatment of patients with breast cancer (Short report) 99
- endometrial cancer
 treatment with paclitaxel (Short report) 861
- endothelium
 influence of 5-fluorouracil and methotrexate 731
- epidemiology
 importance (Editorial) 439
 of cancer 497
 of EBV and Hodgkin's lymphoma (Review) S4: 5
 epidoxorubicin
 distribution in mice (Rapid publication) 801
- epithelial neoplasms
 the role of chemotherapy (Review) S2: 23
- Epstein-Barr virus (EBV)
 after solid organ transplantation 265
 and Hodgkin's disease 265, (Symposium article) S4: 45
 epidemiology and Hodgkin's lymphoma (Review) S4: 5
 its role in the pathogenesis of Hodgkin's disease (Review) S4: 11
- Erwinia chrysanthemi
 exposures to children with acute lymphoblastic leukemia 725
- esophagogastric junction area
 advanced adenocarcinoma (Short report) 533
 treatment with 5-FU and folinic acid (Short report) 533
- esophagus
 advanced adenocarcinoma (Short report) 533

- treatment with 5-FU and folinic acid (Short report) 533
- estrogen receptors**
- in breast cancer cells 391
- estrogenic recruitment**
- in metastatic breast cancer 487
- ethics**
- of euthanasia 907
- European perspective**
- on clinical benefits (Editorial) 333
- euthanasia**
- ethics of 907
- physician-assisted (Editorial)** 879
- versus palliative care (Letter to the editor) 645, (Editorial) 879
- ex vivo expansion**
- of stem cells in mice (Review) S2: 15
- ex vivo purging**
- of peripheral blood progenitor cells (Review) S2: 11
- extradural lymphomas**
- state-of-the-art (Commentary) 787
 - treatment (Commentary) 787
- evaluation criteria**
- for response rates in advanced colorectal cancer (Arena) 901
- F**
- FA administration**
- neurotoxicity (Letter to the editor) 213
- fadrozole**
- versus tamoxifen in patients with advanced breast cancer 471
 - versus tamoxifen in patients with metastatic breast cancer 465
- fallopian tube carcinoma**
- survival analysis 271
- fibrinogen**
- interaction between HRT and tamoxifen 671
- FICTION**
- and the monoclonality of Hodgkin and Reed-Sternberg cells (Review) S4: 49
- financial costs**
- of intravenous infusion with 5-fluorouracil 807
- FISH**
- molecular cytogenetics in Hodgkin's disease (Review) S4: 49
- fixed effects**
- in childhood leukemia clinical research (Arena) 1009
- 5-fluorouracil**
- and methotrexate on vascular endothelium 731
 - as a treatment for patients with advanced colorectal cancer 581
 - as a treatment for patients with advanced pancreatic adenocarcinoma 173
 - as a treatment for patients with biliary tract cancer (Letter to the editor) 644
 - as a treatment for patients with breast cancer (Short report) 409, (Editorial) 771
 - as a treatment for patients with metastatic colorectal carcinoma 575
 - biologically modulated by folinic acid (Letter to the editor) 644
 - comparison of results to tissue dry levels with or without interferon α (Short report) 533
 - folinic acid association 283
 - in advanced adenocarcinoma (Short report) 533
 - in cancer chemotherapy 283
 - in colorectal cancer 41, (Editorial) 551, 581
- in combination therapy in metastatic carcinoid and malignant endocrine pancreatic tumours (Short report)** 208
- in combination with leucovorin** 581
- infusional (Short report)** 55, 409, 581, (Editorial) 771, 807
- measurement of plasma** 47
- neurotoxicity (Letter to the editor)** 213
- phase I/II study** 55, 581
- radiotherapy** 511
- 5-fluorouracil infusion**
- as a treatment for patients with advanced breast cancer 807
- 5-HT3 receptor antagonist**
- compared with placebos and dexamethasone 945
 - for the control of cisplatin-induced delayed emesis 945
- flouxuridine**
- in combination with recombinant α 2b-interferon 601
 - treatment of patients with metastatic renal cell carcinoma 601
- fludarabine**
- as a treatment for patients with LCC 373
 - in therapy of low-grade follicular lymphoma (Review) S6: 41
 - long term survival 373
- folinic acid**
- as a treatment for patients with advanced adenocarcinoma of the esophagus (Short report) 533
 - cancer chemotherapy 283
 - 5-fluorouracil association 283
 - in combination with 5-FU (Short report) 533
 - phase I/II study 55
- follicular lymphoma**
- histological transformation (Clinical case) 849
 - stage Ia 713
 - 2-CDA therapy (Rapid publication) 793
 - wait-and-see policy 713
- follicular small cleaved cell lymphoma**
- treatment with combined chemotherapy-radiotherapy 157
- fractionated radiotherapy**
- prevention of nausea and vomiting in patients 586
- future perspectives**
- for the treatment of Hodgkin's disease (Symposium article) S4: 127
- G**
- G-CSF**
- in elderly patients (Short report) 966
 - in patients with advanced non-small lung cancer and malignant melanoma (Short report) 1080
 - in patients with HIV-related non-Hodgkin's lymphoma 1029
 - in patients with poor-risk non-Hodgkin's lymphoma 1037
- gemcitabine**
- as a treatment for patients with pancreatic cancer (Editorial) 335, (Rapid publication) 347
 - phase II trial (Rapid publication) 347
- gene rearrangement**
- in the peripheral blood of patients with diffuse large B-cell lymphomas 1023
- gene therapy**
- as a new therapy for cancer (Special article) 449
 - expanding cord blood after allogeneic transplantation (Review) S2: 47
 - for patients with metastatic renal cell cancer (Review) 887
 - in peripheral blood progenitor cell transplantation (Introduction) S2: 1

- the challenge for the future (Review) S2: 53
- gene transfer
 - in mice and man (Review) S2: 53
 - genetic testing
 - prevention of hereditary nonpolyposis colorectal cancer (Special article) 891
 - germ cell neoplasms
 - the role of chemotherapy (Review) S2: 23
 - germ-cell tumours
 - carboplatin in combination chemotherapy (Editorial) 989
 - high-dose chemotherapy (Review) 997
- GM-CSF
 - in patients with AML 397
 - in patients with metastatic breast cancer 35
 - treatment with interleukin-10 397
- gonadal dysfunction after chemotherapy
 - late effects in childhood Hodgkin's lymphoma (Review) S4: 67
- graft versus host disease
 - allogeneic transplantation of peripheral blood progenitor cells (Review) S2: 41
 - in chronic myelogenous leukaemia (Review) S2: 19
- granisetron
 - in emetogenic chemotherapy 71
- granulocytic sarcoma
 - isolated (Letter to the editor) 424
- granulocyte colony stimulating factor
 - in allogeneic transplantation of peripheral blood progenitor cells (Review) S2: 41
- granulocyte growth factors
 - in adult solid tumours (Review) S2: 23
 - in haemopoietic stem cells (Review) S2: 5
 - in progenitors (Introduction) S2: 1
 - in stem cells of adult mice (Review) S2: 15
- granulosa cell tumour
 - of the ovary (Clinical case) 521
- growth factors
 - after treatment with pentosan 939
- H**
- haemoptysis
 - in a patient with metastatic carcinoma of the breast (Letter to the editor) 756
- haematopoiesis
 - transplantation of peripheral blood progenitor cells (Review) S2: 41
- haematopoietic stem cells
 - cord blood as an alternative source (Review) S2: 47
 - repopulating ability in mice (Review) S2: 15
 - study of cells in patients (Review) S2: 5
- haematopoietic stem cell transplantation
 - and drug therapy 151
 - in Hodgkin's disease patients 151
- hairy cell leukemia (HCL)
 - involvement of the CCND1 gene 251
- head and neck cancer
 - treatment with chemotherapy 15
- head and neck neoplasms
 - re-irradiation with concomitant chemotherapy 913
- heart transplantation
 - pretransplant malignancy in candidates and posttransplant malignancy in recipients 1059
- Helicobacter pylori*
 - association with MALT lymphoma (Commentary) 787
- hematological recovery
 - prognostic factors for autograft patients 719
- heparan sulfate
 - as a treatment for patients with advanced malignancies 939
- heparinoid
 - pentosan 939
- hepatic artery infusion
 - in liver metastases of colorectal cancer (Short report) 317
 - with interleukin-2 (Short report) 317
- hereditary colon cancer
 - prevention by genetic testing (Special article) 891
- high-dose chemotherapy
 - for Hodgkin's lymphoma (Symposium article) S4: 131
 - for patients with poor-risk non-Hodgkin's lymphoma 1037
 - in germ-cell tumours (Review) 997
- high-dose single agent chemotherapy
 - in Hodgkin's disease (Review) S4: 109
- high-dose VP-16
 - in patients with bone marrow transplantation 83
- high performance liquid chromatography
 - measurement of plasma 5-FU 47
 - treatment of patients with colorectal cancer 47
- histopathology
 - of lymphocyte predominant Hodgkin's disease (Symposium article) S4: 61
- historical control studies
 - compared with randomized trials 355
 - of patients with esophageal carcinoma 355
- HIV
 - hematopoietic colony-stimulating factors (Arena) 233
 - related with non-Hodgkin's lymphoma's (Arena) 233
- Hodgkin's disease
 - analysis of tumor cells (Symposium article) S4: 45
 - autologous hematopoietic rescue 151
 - brief chemotherapy and adjuvant radiotherapy (Review) S4: 105
 - clinical trials (Symposium article) S4: 127
 - complications by second cancers (Clinical case) 405
 - current clinical trials (Review) S4: 109
 - current strategies (Review) S4: 91
 - cytogenetics and molecular cytogenetics (Review) S4: 49
 - development of immunotoxins for potential use (Review) S4: 135
 - early high dose chemotherapy (Symposium article) S4: 131
 - early stage (Editorial) 115, (Review) 85, 91
 - evidence of the Epstein-Barr virus 265
 - following solid organ transplantation 265
 - Ig rearrangements in isolated Reed-Sternberg cells (Review) S4: 31
 - increased risks in females 257
 - interactive signals in the pathobiology (Review) S4: 19
 - late complications (Review) S4: 115
 - long-term results of radiotherapy 145
 - management of early stage (Review) S4: 79
 - meningeal localization in a patient (Clinical case) 1071
 - occurrence of cardiopulmonary sequelae 257
 - patients with an incomplete response to front-line therapy 1043

- preliminary experience with paclitaxel (Short report) 1083
 present and future strategies of treatment in childhood (Review) S4: 73
 rationale for dose escalation of first line conventional chemotherapy (Review) S4: 95
 role of Epstein-Barr virus in the pathogenesis (Review) S4: 11
 role of radiation therapy and/or chemotherapy (Review) S4: 79
 role of radiation therapy in advanced disease (Review) S4: 99
 single cell analysis of Hodgkin/Reed-Sternberg cells (Review) S4: 27, 41
 single cell PCR for the analysis (Review) S4: 35
 treatment (Special article) 555
 treatment with bispecific antibodies (Review) S4: 143
 treatment with high-dose chemotherapy 151
Hodgkin's lymphoma
 epidemiology (Review) S4: 5
 overview of the Third International Symposium (Introduction) S4: 1
hormonal replacement therapy
 as a treatment for patients with a breast cancer history (Editorial) 655
 effect on serum cholesterol, bone mineral density and coagulation factors 671
 interaction with tamoxifen 671
HUMARA gene assay
 in single cell analysis of H/RS cells (Review) S4: 41
hypnotics
 discontinuation in terminal cancer patients (Short report) 855
- I**
- ifosfamide**
 as a treatment for patients with advanced ovarian cancer (Short report) 419
 as a treatment for patients with malignant melanoma (Short report) 1080
 as a treatment for patients with non-small-cell lung cancer (Short report) 311, 314, 747, (Short report) 637, (Short report) 1080
 in combination with methylene-blue (Letter to the editor) 643
 in salvage therapy (Short report) 419
 phase I study (Short report) 311, 314
 phase II study (Short report) 637, (Short report) 1080
 oral versus intravenous (Short report) 637
Ig gene rearrangements
 in Hodgkin/Reed-Sternberg cells (Review) S4: 27
imaging procedures
 in Hodgkin's disease (Review) S4: 55
immunogenotype
 in lymphocytic leukemia (Clinical case) 953
immunoglobulin gene rearrangement
 by PCR in single cell analysis of H/RS cells S4: 41
immunoglobulin heavy chain rearrangements
 in HRS cells (Review) S4: 35
immunoglobulin rearrangement
 in isolated Reed-Sternberg cells (Review) S4: 31
immunohistochemistry
 detection of MRP expression 75
 in hairy cell leukemia 251
 involvement of the CCND1 gene 251
 involvement of the LRP gene 625
immunophenotype
 in lymphocytic leukemia (Clinical case) 953
immunoscintigraphy
 new diagnostic procedure in Hodgkin's disease (Review) S4: 55
immunotherapy
 of Hodgkin's disease (Review) S4: 143
 of metastatic renal cell cancer (Review) 887
 monitoring of cancer vaccines (Commentary) 667
immunotoxin
 development for potential clinical use in Hodgkin's disease (Review) S4: 135
in vitro expansion
 of haemopoietic stem cells (Review) S2: 47
in vivo purging
 of peripheral blood progenitor cells (Review) S2: 11
incidence
 and mortality 497
Indiana University classification
 randomized trial for patients with good-risk metastatic non-seminomatous germ cell tumours 1015
indoloquinone EO9
 in non-small-cell lung cancer (Short report) 529
induction failure
 in patients with lymphoma 1043
inflammatory disease
 dose-response effect (Review) S2: 31
infusional
 CMF (Short report) 409
inter-abdominal abscess
 complications for chemotherapy (Letter to the editor) 536
interaction
 between paclitaxel and EpiDx (Rapid publication) 801
interferon
 as a treatment for patients with colorectal cancer patients 47
 as a treatment for patients with metastatic renal cell carcinoma 601
 in combination with flouxuridine 601
interferon- α
 as a treatment for patients with chronic myelogenous leukaemia (Review) S2: 19
 as a treatment for patients with metastatic melanoma 827
 in combination with biotherapy 827
intergroup trials
 prospective meta-analysis strategy (Arena) 1005
interleukin-2
 as a treatment for out-patients with metastatic renal cell carcinoma (Short report) 525
 as a treatment for patients with colorectal cancer (Short report) 317
 as a treatment for patients with metastatic melanoma 827
 prolonged continuous hepatic artery infusion (Short report) 317
 phase I study (Short report) 317
 peripheral nerve entrapment (Letter to the editor) 535
interleukin-10
 for patients with AML 397
 inhibition of cytokine production 397
interleukins
 as a treatment for patients with metastatic renal cell cancer (Review) 887
intermediate- to high-grade non-Hodgkin's lymphomas
 combined modality treatment 919
investigational agents
 in patients with refractory malignancies 491
irinotecan
 dosage schedules 837

- islet cell**
 combination therapy with interferon- α -2a and 5-FU (Short report) 208
- isolated granulocytic sarcoma**
 of the breast (Letter to the editor) 424
- L**
- L-asparaginase**
 exposure to *Erwinia* 725
- L-asparagine depletion**
 in children with acute lymphoblastic leukemia 725
- laboratory**
 research of ovarian cancer 9
- large cell lymphoma**
 clinical significance of bcl-2 (MBR)/JH rearrangement in the peripheral blood 1023
- late complications**
 after Hodgkin's disease (Review) S4: 115
- late effects of chemotherapy**
 in childhood Hodgkin's lymphoma (Review) S4: 67
- leptomeningitis**
 carcinomatous meningitis (Review) 773
- letrozole**
 as a treatment for patients with breast cancer (Short report) 99
- leucovorin**
 as a treatment for patients with advanced colorectal cancer 581
 as a treatment for patients with advanced pancreatic adenocarcinoma 173
 in combination with 5-FU 581
- leukaemia**
 complicating Hodgkin's disease (Clinical case) 405
- levamisole**
 role in treatment of patients with colorectal cancer 41
- ligands**
 TNF superfamilies in the pathobiology of Hodgkin's disease (Review) S4: 19
- limited stages**
 causing complications 713
- LMPI**
 pathogenesis of Hodgkin's disease (Review) S4: 11
- localized**
 stage NHL 919
- locally advanced breast cancer**
 efficacy and safety of docetaxel 165
- low-dose continuous**
 intravenous infusion of 5-fluorouracil 807
- low-grade follicular lymphoma**
 purine nucleoside therapy (Review) S6: 41
- lung cancer**
 carcinomatous meningitis (Review) 773
 expression of the LRP protein 625
 non-small-cell (Editorial) 119, (Short report) 311, 314
 phase I study (Short report) 311, 314
 radiotherapy preceded by high-dose chemotherapy versus high-dose radiotherapy 139
 randomized phase II trials (Letter to the editor) 755
 role of surgery in small-cell (Clinical case) 303
 treatment with chemotherapy (Short report) 311, 314
- lung neoplasms**
 the role of chemotherapy (Review) S2: 23
- lung resistance-related protein (LRP)**
 expression in human lung cancer 625
 role in drug resistance 625
- lymphoma**
 clonal analysis (Clinical case) 953
 evolution into lymphocytic leukemia (Clinical case) 953
 treatment with a pirarubicin-combination chemotherapy regimen (Short report) 966
 treatment with paclitaxel (Short report) 1083
- lymphopoiesis**
 reconstruction after allogeneic transplantation of peripheral blood progenitor cells (Review) S2: 41
- lymphocyte predominance Hodgkin's disease**
 a workshop report (Symposium article) S4: 61
- M**
- magnetic resonance spectroscopy**
 of colorectal cancer 47
- malignancy**
 in recipients of cardiac transplantation 1059
- malignant glioma**
 phase II study (Short report) 205
- MALT lymphoma**
 combined modality therapy (Letter to the editor) 211
Helicobacter pylori (Commentary) 787
 purine analogs (Review) S6: 21
 state-of-the-art (Commentary) 787
- MALToma**
 new classification (Review) S6: 3
- management**
 of patients with tumour lysis syndrome (Clinical case) 631
- mantle cell lymphoma (MCL)**
 classification and therapeutic implications (Review) S6: 35
 treatment with combined modality therapy (Letter to the editor) 211
- marginal-zone lymphomas**
 purine analogs (Review) S6: 21
- marrow repopulation**
 in mice (Review) S2: 15
- maspin**
 reverse-transcriptase polymerase chain reaction of 619
 role in breast cancer 619
- matrix attachment regions**
 in cancer therapy (Review) 659
- melanoma**
 identification in peripheral blood 297
 treatment with biochemotherapy 827
- melphalan**
 as a treatment for patients with ovarian cancer 65
- meningeal lymphoma**
 in patients with Hodgkin's disease (Clinical case) 1071
- meta-analysis**
 strategy in childhood leukemia clinical research (Arena) 1009
- metabolism**
 in patients with breast cancer 291
 of 8-chloroadenosine 3',5'-monophosphate 291
- metastasis**
 treatment with neoadjuvant chemotherapy (Short report) 864
- metastatic breast cancer**

- treatment with chemotherapy 487
 clubbing, arthralgia and haemoptysis (Letter to the editor) 756
 detection of 619
 efficacy and safety of docetaxel 165
 maspin gene 619
 metastatic colorectal carcinoma
 treatment with 5-fluorouracil plus α -interferon 575
 metastatic disease
 dose intensification (Review) S2: 31
 metastatic liver disease
 results of cancer treatment (Letter to the editor) 871
 metastatic renal cell carcinoma
 treatment with flouxuridine plus interferon α -2b-interferon 601
 metastatic spinal cord compression
 in patients with small-cell lung cancer (Letter to the editor) 321
 methadone
 as a treatment for patients with cancer pain 613
 methodology
 phase I trials (Review) 561
 methotrexate
 in gene therapy (Review) S2: 53
 as a treatment for patients with solid tumours 59
 methylene-blue
 in combination with ifosfamide (Letter to the editor) 643
 mice
 repopulating ability (Review) S2: 15
 micromanipulation
 of single Hodgkin/Reed-Sternberg cells (Review) S4: 27
 mitomycin-C
 as a treatment for patients with biliary tract cancer (Letter to the editor)
 644
 mitoxantrone
 as a treatment for patients with adenoid cystic carcinomas (Short report)
 867
 as a treatment for patients with advanced ovarian cancer (Short report)
 419
 as a treatment for patients with breast cancer (Short report) 745
 salvage therapy (Short report) 419
 molecular tumour markers
 and clonality (Review) 121
 monitoring of cancer vaccines
 immunotherapy (Commentary) 667
 monocytoid B-cell lymphomas
 purine analogs (Review) S6: 21
 mortality
 trends in cancer 497
 MRI (magnetic resonance imaging)
 diagnostic imaging procedure in Hodgkin's disease (Review) S4: 55
 multicentric
 osteosarcoma (Short report) 864
 multidrug resistance
 in lung cancer 625
 LRP protein 625
 multidrug resistance-associated protein (MRP)
 expression in lung cancer 625
 in NSCLC 75
 relation with LRP 635
 multifocal leukoencephalopathy
- treatment of patients with colon cancer (Short report) 412
 multiple myeloma
 treatment with oral idarubicin and prednisone (Letter to the editor) 537
- N
- N-myc
 treatment of patients with neuroblastoma 183
 nausea
 induced by low-dose cisplatin- or non-cisplatin-containing chemotherapy
 505
 comparing the effect of ondansetron plus dexamethasone and metoclopramide plus dexamethasone 277
 neo-adjuvant chemotherapy
 versus radiotherapy in non-small-cell lung cancer 139
 nephrotoxicity
 in chemotherapy for patients with non-small-cell lung cancer (Short report)
 529
 neuroblastoma
 diagnostic and prognostic value of biological markers 607
 patterns of stages I, II and III 183
 neuroendocrine gastrointestinal tumours
 management of the disease (Review) 453
 neuroendocrine tumours
 combination therapy with interferon- α -2a and 5-fluorouracil (Short report)
 208
 neurotoxicity
 related to 5-fluorouracil and FA administration (Letter to the editor) 213
 node-negative breast cancer
 adjuvant treatment 481
 non-cisplatin-containing regimen
 as a treatment for patients with non-small-cell lung cancer 821
 non-Hodgkin's lymphoma
 activity of single agent vinorelbine (Short report) 970
 classification and clinical course (Review) S6: 13
 hematopoietic colony-stimulating factors (Arena) 233
 HIV-related (Arena) 233
 intensive therapy and autotransplant 1043
 MALT lymphoma's (Commentary) 787
 new classification (Review) S6: 3
 new prognostic factors (Editorial)
 state-of-the-art (Commentary) 787
 therapy in HIV-related diseases 1029
 treatment with combined modality therapy 825
 treatment with high-dose CDE with G-CSF without stem-cell support
 1037
 use of new agents (Editorial) 767
 nonmalignant complications
 after Hodgkin's disease (Review) S4: 115
 non-small-cell lung cancer
 expression of MRP 75
 more power to trials (Editorial) 119
 phase I study (Short report) 311, 314
 phase II study (Short report) 747, (Short report) 637, 821
 treatment with chemotherapy (Short report) 311, 314, (Short report) 637
 treatment with ifosfamide/mesna 637
 treatment with vinorelbine and vindesine #15
 VIP and VIP-16 combination chemotherapies 517
 nuchal liposarcoma

- cell transplantation (Letter to the editor) 871
 inoperable relapse (Letter to the editor) 871
 nuclear matrix
 as a target for cancer therapy (Review) 659
 nucleoside analogue
 long-term survival 373
 as a therapy for patients with CLL 373
- O**
- octreoscan
 localizing neuroendocrine gastrointestinal tumours (Review) 453
- OEPA
 used in chemotherapy for childhood Hodgkin's lymphoma (Review) S4: 67
- oesophageal neoplasms
 treatment with chemotherapy 355
- onapristone
 antiproliferative potency 391
 as a treatment for patients with breast cancer 391
 stimulation of TGF-beta 391
- ondansetron
 as a treatment for cisplatin-induced emesis 277, 945
 as a treatment for patients undergoing fractionated radiotherapy 587
 compared with metoclopramide dexamethasone plus lorazepam 277
 compared with placebos and dexamethasone 945
 preventing nausea and vomiting 587, 945
- OPA
 used in chemotherapy for childhood Hodgkin's lymphoma (Review) S4: 67
- OPPA
 used in chemotherapy for childhood Hodgkin's lymphoma (Review) S4: 67
- oral idarubicin
 as a treatment for patients with advanced multiple myeloma (Letter to the editor) 537
- organ transplantation
 evidence of Epstein-Barr virus 265
 as a treatment for patients with Hodgkin's disease 265
- osteosarcoma
 synchronous multifocal (Short report) 864
 treatment with neoadjuvant chemotherapy (Short report) 864
- out-patient
 with metastatic renal cell carcinoma (Short report) 525
- ovarian cancer
 CA 125 levels 361
 challenges for the future (Special article) 9
 paclitaxel/cisplatin as initial therapy (Short report) 1077
 progression 361
 salvage therapy (Short report) 419
 treatment with ifosfamide and mitoxantrone (Short report) 419
 treatment with surgery, short-course chemotherapy and whole abdominal radiation 65
 oxaliplatin
 phase II study (Short report) 95
 single agent activity in advanced ovarian cancer 1065
- P**
- p53
- in patients with node-positive breast carcinoma 695
 paclitaxel
 as a treatment for patients with advanced breast cancer 687, (Short report) 857
 as a treatment for patients with advanced endometrial cancer (Short report) 861
 as a treatment for patients with advanced ovarian cancer (Short report) 1077
 as a treatment for patients with germ-cell tumours (Review) 997
 as a treatment for patients with Hodgkin's disease (Letter to the editor) 423
 as a treatment for patients with non-Hodgkin's lymphoma (Letter to the editor) 423
 as a treatment for patients with non-small-cell lung cancer (Short report) 311, 314
 as a treatment for patients with relapsed and refractory Hodgkin's disease (Short report) 1083
 as a treatment for patients with solid tumours 59
 inducing changes in epidoxorubicin (Rapid publication) 801
 inducing radiation recall dermatitis (Letter to the editor) 755
 phase I study (Short report) 311, 314
 phase II study 31, (Short report) 857, (Short report) 861
 prevention of hypersensitivity (Letter to the editor) 978
- palliation
 in patients with advanced colorectal cancer (Short report) 961
 use of chemotherapy 593
- palliative care
 and cancer patients (Arena) 135
 versus euthanasia (Letter to the editor) 645, 907
- palliative therapy
 for patients with breast cancer 807
- pancreatic cancer
 improvement of quality of life 593
 phase II trial (Rapid publication) 347
 prolongement of survival 593
 treatment with gemcitabine (Editorial) 335, (Rapid publication) 347
 use of chemotherapy 593
- paragranuloma
 classification of lymphocyte predominant Hodgkin's disease cases (Symposium article) S4: 61
- paraplegia
 in patients with small-cell lung cancer (Letter to the editor) 321
- pathogenesis
 of Hodgkin's disease (Review) S4: 19
- patient-controlled analgesia
 use of methadone in cancer pain 613
- patterns of care
 of elderly cancer patients 677
- patterns of relapse
 effects of prednisone combined with CMF 245
 in patients with breast cancer 245
- pediatric oncology
 clinical research in childhood ALL (Arena) 1005
- pentosan
 as a treatment for patients with advanced malignancies 939
- peripheral blood
 autotransplant of progenitor cells 719
 cell mobilisation following G-CSF 1051

- peripheral blood progenitor cells (Introduction) S2: 1
 in adult solid tumours other than breast cancer (Review) S2: 23
 in chronic myelogenous leukaemia (Review) S2: 19
 purging of (Review) S2: 11
 peripheral blood stem cells
 dose intensification in patients with breast cancer (Review) S2: 31
 gene therapy (Review) S2: 53
 mobilisation and collection (Review) S2: 9
 repopulating ability in mice (Review) S2: 15
 peripheral nerve entrapment
 high-dose interleukin-2 therapy (Letter to the editor) 535
 pharmacokinetics
 application schedules in patients with bone marrow transplantation 83
 anthracyclines (Rapid publication) 801
 8-chloroadenosine 3',5'-monophosphate 291
 in breast cancer patients 291
 pharmacomodulation
 5-fluorouracil-folinic acid association 283
 phase I trials
 of methotrexate and paclitaxel with and without G-CSF 59
 methodology (Review) 561
 of bi-weekly paclitaxel/cisplatin as therapy for advanced ovarian cancer
 (Short report) 1077
 of pentox 939
 phase I/II trials
 of 5-FU plus high-dose folinic acid 55
 phase II trials
 of a closely spaced ifosfamide-cisplatin schedule with the addition of G-CSF (Short report) 1080
 of CAP regimen (Short report) 640
 of 5-FU in combination with leucovorin 581
 of flouxuridine plus recombinant α -2b-interferon 601
 of mitoxantrone (Short report) 867
 of mitomycin-C in combination with 5-fluorouracil (Letter to the editor) 644
 of oral ifosfamide versus intravenous ifosfamide (Short report) 637
 of oxaliplatin (Short report) 95
 of paclitaxel 31
 of 13-cis retinoic acid plus interferon- α (Letter to the editor) 539
 of topotecan (Short report) 205
 Philadelphia negative cells
 in chronic myelogenous leukaemia (Review) S2: 19
 platinum induction
 as induction chemotherapy for patients with small-cell lung cancer 365
 polymerase chain reaction (PCR)
 detection of peripheral blood bcl-2 (MBR)/JH rearrangement 1023
 detecting the nature of HRS cells (Review) S4: 31
 for analysis of Hodgkin's disease (Review) S4: 35
 polymers
 in cancer chemotherapy (Special article) 445
 positron emission tomography (PET)
 as a method to diagnose residual disease (Short report) 416
 as a method to diagnose tumour emboli (Short report) 416
 in choriocarcinoma (Short report) 416
 new diagnostic imaging procedure in Hodgkin's disease (Review) S4: 55
 postmenopausal
 patients with metastatic breast cancer 465
 prednisone
 as a treatment for advanced multiple myeloma (Letter to the editor) 537
 combined with CMF 245
 development of bone metastases (Letter to the editor) 643
 effects of treatment in patients with breast cancer 245
 effects on patterns of relapse 245
 prevention
 of hereditary nonpolyposis colorectal cancer (Special article) 891
 previously untreated stages IIIB or IV non-small cell lung cancer
 treatment with vinorelbine and vindesine 815
 primary surgery
 as a treatment for patients with small-cell lung cancer 303
 prochlorperazine
 as antiemetic (Editorial) 103
 progenitor assays
 standards for PBSC mobilisation and collection (Review) S2: 9
 progenitor thresholds
 standards for PBSC mobilisation and collection (Review) S2: 9
 progesterone receptors
 in breast cancer cells 391
 stimulation of TGF-beta 391
 prognosis
 anti-cancer serological response (Review) 227
 by biological markers 607
 for patients with follicular lymphoma (Clinical case) 849
 for patients with lymphocyte predominant Hodgkin's disease (Symposium article) S4: 61
 of cyclin D1 in patients with node-positive breast carcinoma 699
 of neuroblastoma 607
 prognostic factors
 associated with hematopoietic recovery in autograft patients 719
 developed from clinical trials of early stage Hodgkin's disease (Review) S4: 80
 expression of Bax in relation to Bcl-2 (Rapid publication) 129
 in patients with breast cancer (Rapid publication) 129
 in patients with diffuse large cell non-Hodgkin's lymphoma (Editorial) 993
 in patients with early stage Hodgkin's disease (Review) S4: 79, 91
 in patients with germ-cell tumours (Review) 997
 in patients with good-risk metastatic non-seminomatous germ cell tumours 1015
 of t(14;18) in the blood of patients with DLCL 1023
 using early high dose chemotherapy on patients with Hodgkin's disease (Symposium article) S4: 131
 progression
 according to CA 125 361
 of ovarian carcinoma 361
 prospective meta-analysis
 strategy for inter-group collaboration (Arena) 1005
 prostacyclin
 release by the bovine endothelial cells 731
 psychology
 patient perceptions of the effects of chemotherapy 189
 psycho-oncology
 palliative and supportive care (Arena) 135
 pulmonary sequelae
 after treatment for Hodgkin's disease 257
 increased risks in females 257
 pulmonary toxicity

- after treatment with high-dose vinorelbine and mitomycin C (Short report) 973
- purgung**
- of peripheral blood progenitor cell transplantation (Introduction) S2: 1
 - purine analogs
 - in chronic lymphocytic leukemia and Waldenström's macroglobulinemia (Review) S6: 27
 - in mantle-cell lymphoma (Review) S6: 35
 - in marginal-zone lymphomas (Review) S6: 21
 - therapy of low-grade follicular lymphoma (Review) S6: 41
 - therapy of low-grade non-Hodgkin's lymphomas (Review) S6: 13
- Q**
- quality of life**
- CARES-SF as an instrument in clinical trials 381
 - improvement by treatment with FU-LDCI 807
 - of patients with breast cancer 807
 - of patients with Hodgkin's disease (Review) S4: 115
 - of patients with pancreas cancer (Rapid publication) 347
 - prevention of nausea and vomiting 587
- R**
- radiation**
- recall dermatitis (Letter to the editor) 755
 - in Hodgkin's disease 257
 - increased risks in females 257
 - paclitaxel-induced (Letter to the editor) 755
 - pulmonary sequelae 257
 - therapy for patients with anaplastic carcinoma of the thyroid (Clinical case) 739
 - therapy for patients with bulky or advanced Hodgkin's disease (Review) S4: 105
- radioprotection**
- therapy for patients with advanced Hodgkin's disease (Review) S4: 99
 - short-term repopulating ability in mice (Review) S2: 15
- radiotherapy**
- as a treatment for patients with Hodgkin's disease (Special article) 555, (Review) S4: 109, (Clinical case) 1071
 - as a treatment for patients with locally advanced carcinoma of the cervix 511
 - clinical stage I and II Hodgkin's disease 145
 - combined with chemotherapy in NHL 919
 - of low-grade non-Hodgkin's lymphomas (Review) S6: 13
 - role in management of early stage Hodgkin's disease S4: 79
 - setrons (Editorial) 553
 - versus radiotherapy preceded by high-dose chemotherapy in non-small-cell lung cancer 139
- random effects**
- in meta-analysis in childhood leukemia clinical research (Arena) 1009
- randomization**
- in meta-analysis in childhood leukemia clinical research (Arena) 1009
- randomized**
- phase II trial in lung cancer (Letter to the editor) 755
 - phase II trial in non-small-cell lung cancer 815
- randomized clinical trials**
- for patients with advanced Hodgkin's disease (Review) S4: 95
- randomized controlled trials**
- compared to historical control studies 355
- for patients with esophageal carcinoma 355
- randomized trial**
- in childhood ALL: the prospective meta-analysis strategy for inter-group collaboration (Arena) 1005
 - investigating the dose intensity of primary chemotherapy in patients with ovarian carcinoma 705
 - investigating chemotherapy for the improvement of survival and quality of life 593
 - of PEB versus CEB 1015
- REAL classification**
- of mantle-cell lymphoma S6: 35
- receptors**
- TNF superfamilies in the pathobiology of Hodgkin's disease (Review) S4: 19
- recurrence**
- of head and neck neoplasms 913
 - of neuroblastomas 183
- Reed-Sternberg cell**
- single cell analysis (Review) S4: 27, 41
- refractory lymphoma**
- intensive therapy and autotransplant 1043
- registry**
- of mortality 497
- re-irradiation**
- of recurrent head and neck cancer 913
- relapse**
- in patients with ovarian cancer 361
- remission**
- after 2-CdA therapy 373
 - in patients with CLL 373
- renal cell carcinoma**
- treatment of patients with flouxuridine plus recombinant α 2b-interferon 601
 - treatment of patients with interferons and interleukin-2 (Review) 887
 - treatment of patients with subcutaneous recombinant interleukin-2 (Short report) 525
- renal failure**
- occurrence in patients with tumour lysis syndrome (Clinical case) 631
- repeated treatments**
- with cisplatin induced emesis 277
- residual disease**
- diagnosis of (Short report) 416
 - in choriocarcinoma (Short report) 416
- resistance mechanisms**
- in gene therapy (Review) S2: 53
- response**
- to dose escalation schemes (Commentary) 567
 - phase I trials (Commentary) 567
- response rate**
- effect of radiotherapy preceded by chemotherapy versus radiotherapy 139
 - of patients with locally advanced non-small-cell lung cancer 139
- retroviral vectors**
- gene therapy (Review) S2: 53
- Review**
- allogeneic transplantation of peripheral blood progenitor cells S2: 41
 - carcinomatous meningitis in solid tumour 773
 - chemotherapy for squamous cell carcinoma of head and neck 15

- development of immunotoxins for potential clinical use in Hodgkin's disease S4: 135
- dose intensification and breast cancer: Current results and future perspectives S2: 31
- gene therapy - the challenge for the future S2: 53
- immunotherapy of metastatic renal cell cancer 887
- mobilization of Ph1-negative blood progenitor cells in chronic myelogenous leukaemia S2: 19
- neuroendocrine gastrointestinal tumours 453
- new classification of low-grade lymphoma S6: 3
- 1975-1995 revised anti-cancer serological response 227
- nuclear matrix as a target for cancer therapy 659
- peripheral blood progenitor cell transplantation (Introduction) S2: 1
- phase I trial design 561
- recognition of tumour-associated antigens by T-lymphocytes 339
- role of high dose chemotherapy in adult solid tumours other than breast cancer S2: 23
- standards for PBSC mobilisation and collection S2: 9
- study of haemopoietic stem cells in patients S2: 5
- tumour heterogeneity and clonality 121
- RFT5-SMPT-dgA
 - for potential use in Hodgkin's disease (Review) S4: 135
- Rhodamine 123
 - purification of stem cells (Review) S2: 15
- risk-factor
 - for patients with neuroblastoma 183
- RNA
 - CCND1 gene 251
 - and hairy cell leukemia 251
- RNase protection assay
 - in treatment of NSCLC 75
- Rosai-Dorfman Syndrome
 - transformation into high-grade lymphoma (Letter to the editor) 977
- RT-PCR
 - for identification of breast cancer cells 619
 - for identification of melanoma cells in peripheral blood 297
- S**
- salvage therapy
 - in heavily pretreated advanced epithelial ovarian cancer 1065
 - in pretreated non-Hodgkin's lymphomas (Short report) 970
- screening
 - by biological markers 607
 - of patients with neuroblastoma 183, 607
- second cancers
 - in Hodgkin's disease (Clinical case) 405
 - leukemia (Clinical case) 405
- second-look surgery
 - of ovarian cancer 65
- second malignancies
 - effects of adjuvant chemotherapy 239
 - treatment with tamoxifen 239
- secondary cancers
 - late complications after Hodgkin's disease (Review) S4: 115
- secondary neoplasm
 - effects of adjuvant prednisone combined with CMF 245
 - in patients with breast cancer 245
- serological response
 - biological and significance and clinical implications (Review) 227
 - serum bFGF
 - in advanced colorectal cancer 843
 - serum VEGF
 - in advanced colorectal cancer 843
 - setrons
 - radiotherapy (Editorial) 553
 - SHML
 - transformation into high-grade lymphoma (Short report) 977
 - side effects
 - of cancer chemotherapy 189
 - single cell analysis
 - of Reed-Sternberg cells (Review) S4: 31
 - single cell isolation
 - in the analysis of Hodgkin's disease (Review) S4: 35
 - single cell PCR
 - analysis of Hodgkin-Sternberg cells (Review) S4: 27
 - small-cell lung cancer
 - treatment with induction chemotherapy 365
 - paraplegia in patients (Letter to the editor) 321
 - purging of peripheral blood cells (Review) S2: 11
 - randomized trial 365
 - the role of surgery (Clinical case) 303
 - solid tumours
 - treatment with CPT-11 837
 - sequential use of methotrexate and paclitaxel 59
 - solitary pulmonary nodule
 - role of surgery 303
 - somatostatin analogue
 - in chemotherapy of neuroendocrine gastrointestinal tumours (Review) 459
 - somatostatin receptor scintigraphy
 - new diagnostic imaging procedure in Hodgkin's disease (Review) S4: 55
 - splenectomy
 - need for management of early stage Hodgkin's disease (Review) S4: 79
 - stage I and II
 - long-term results of radiotherapy 145
 - low-grade lymphoma 157
 - MALT lymphoma (Letter to the editor) 211
 - of Hodgkin's disease 145
 - of non-Hodgkin's lymphomas 825
 - stage I and II low-grade lymphoma
 - treatment with combined chemotherapy-radiotherapy 157
 - stage IV non-small-cell lung cancer
 - treatment with non-cisplatin-containing regimen 821
 - staging
 - small-cell lung cancer 303
 - statistical models
 - used in clinical trials of advanced Hodgkin's disease (Review) S4: 95
 - stem cell assays
 - in the study of haemopoietic stem cells in patients (Review) S2: 5
 - stem cell transplantation
 - allogeneic transplantation of peripheral blood progenitor cells (Review) S2: 41
 - standards for PBSC mobilisation and collection (Review) S2: 9
 - subcutaneous administration
 - of rIL-2 in out-patients (Short report) 525
 - sulfated polysaccharides

- in patients with refractory malignancies 491
- supportive care
 - and cancer patients (Arena) 135
- surgery
 - as a treatment for patients with bone sarcomas (Short report) 864
- survival
 - subcutaneous rIL-2 programs (Short report) 525
 - of patients with advanced endometrial cancer (Short report) 861
 - of patients with head and neck cancer 913
- survival analysis
 - of primary carcinoma of the fallopian tube 271

- T**
- t(11;14)
 - involvement of the CCND1 gene 251
- t(14;18) chromosomal translocation
 - detecting cells (Rapid publication) 793
 - in patients with DLCL 1023
 - in patients with non-Hodgkin's lymphoma (Rapid publication) 793
- t-AML
 - occurrence following adjuvant chemotherapy for breast cancer (Short report) 745
- t-MDS
 - occurrence following adjuvant chemotherapy for breast cancer (Short report) 745
- tamoxifen
 - effect in healthy postmenopausal women 671
 - treatment for early breast cancer 239
 - versus fadrozole in patients with advanced breast cancer 465, 471
- taxoids
 - docetaxel 165
 - as a treatment for patients with advanced breast cancer 165
- taxol
 - preliminary experience with paclitaxel for treatment of Hodgkin's disease (Short report) 1083
- TCNU
 - in colorectal cancer (Letter to the editor) 211
- testicular cancer
 - treatment with paclitaxel (Rapid publication) 31
 - treatment with PEB *versus* CEB 1015
- TGF-beta
 - induction by an antiprogestin 391
 - in human breast cancer cells 391
 - stimulation of growth due to onapristone 391
- therapy
 - anti-cancer serological response (Review) 227
 - for early stage Hodgkin's disease (Review) S4: 91
- Third International Symposium (Introduction) S4: 1
- thymidylate synthase inhibitor
 - antitumour activity in a range of solid tumours 179
 - tomudex (Short report) 961
- thyroid cancer
 - anaplastic (Clinical case) 739
- time intensification
 - regimen in advanced stages of Hodgkin's disease (Review) S4: 109
- time trends
 - in cancer incidence and mortality 497
- TNF

- receptor and ligand superfamilies in the pathobiology of Hodgkin's disease (Review) S4: 19
- Tomudex (ZD 1694)
 - antitumour activity in a range of solid tumours 179
 - as a treatment for patients with advanced colorectal cancer (Short report) 961
 - compared with 5-FU plus leucovorin 945
 - results of a randomised trial (Short report) 961
- topoisomerase II
 - activity in cancer drugs (Review) 659
 - chemotherapy for patients with breast cancer (Short report) 745
- topotecan
 - phase II study in patients with recurrent malignant glioma (Short report) 205
- total dose
 - in therapy for patients with colorectal cancer 41
- toxicity
 - of application schedules in patients with bone marrow transplantation 83
 - of cisplatin-based combination chemotherapy for patients with non-seminomatous germ cell tumours 1015
 - of early high-dose chemotherapy (Symposium article) S4: 131
 - of high-dose CDE with G-CSF in poor-risk non-Hodgkin's lymphoma 1037
 - of high-dose radiotherapy for patients with non-small-cell lung cancer 139
 - of high-dose radiotherapy preceded by chemotherapy for patients with non-small-cell lung cancer 139
 - of dose escalation schemes (Commentary) 567
 - risks for patients with bulky or advanced Hodgkin's disease (Review) S4: 105
- toxicology
 - phase I trials (Commentary) 567
 - responses to dose escalation schemes (Commentary) 567
- transformation
 - of indolent lymphoma (Clinical case) 849
- transition
 - from patients with neuroblastoma 183
- transplantation
 - of peripheral blood progenitor cells (Introduction) S2: 1, (Review) S2: 11, (Review) S2: 23
- treatment
 - of HIV-related non-Hodgkin's lymphomas (Arena) 233
 - of Hodgkin's disease in children (Review) S4: 67, 73
 - of patients with CLL 373
 - of patients with follicular lymphoma (Clinical case) 849
 - of patients with granulosa cell tumour of the ovary (Clinical case) 521
 - of patients with Hodgkin's disease (Review) S4: 109
 - options for early stage Hodgkin's disease (Review) S4: 91
 - usefulness of colony-stimulating factors (Arena) 233
 - with 2-CdA 373
- tropisetron
 - for the control of nausea and vomiting by chemotherapy 505
- tumour-enteric fistula formation (Letter to the editor) 536
- tumour antigens
 - perspectives for peptide-based vaccines (Review) 339
 - recognition by T-lymphocytes (Review) 339
- tumour-associated antigens (TAA)
 - anti-cancer serological response (Review) 227
- tumour biopsies

- in patients with breast cancer 291
of 8-chloroadenosine 3',5'-monophosphate 291
- tumour cell phenotype
pathogenesis of Hodgkin's disease (Review) S4: 11
- tumour emboli
diagnosis (Short report) 416
in choriocarcinoma (Short report) 416
- tumour growth
kinetics in advanced Hodgkin's disease (Review) S4: 95
role of bFGF and VEGF 843
- tumour heterogeneity
and clonality (Review) 121
- tumour lysis syndrome
review of literature (Clinical case) 631
- tumour marker
CA 125 361
- tumour response
in advanced colorectal cancer chemotherapy (Arena) 901
- tumour vaccines
as a treatment for patients with metastatic renal cell cancer (Review) 887
- tumour volume
criteria for response (Letter to the editor) 871
- 2-CdA-therapy
as a treatment for patients with chronic lymphocytic leukemia 373
as a treatment for patients with non-Hodgkin's lymphoma (Rapid publication) 793
- long-term survival 373
- 2-clorodeoxyadenosine
in therapy of chronic lymphocytic leukemia and Waldenström's macroglobulinemia (Review) S6: 27
in therapy of low-grade follicular lymphoma (Review) S6: 41
- 2'-deoxycoformycin
in therapy of chronic lymphocytic leukemia (Review) S6: 27
in therapy of low-grade follicular lymphoma (Review) S6: 41
- tyrosinase
expression of 297
as a method to identify melanoma cells in peripheral blood 297
- RT-PCR 297
- V**
- vaccination
anti-cancer serological response (Review) 227
- vaccines
used in cancer chemotherapy (Special article) 445
- validation
of CARTES-SF as a quality of life instrument 381
- vindesine
as a treatment of patients with non-small-cell lung cancer 815
versus vinorelbine 815
- vinorelbine
acute pulmonary toxicity (Short report) 973
as a treatment of patients with breast cancer (Short report) 857
as a treatment of patients with non-small-cell lung cancer 815
as a treatment of patients with advanced NSCLC (Short report) 747
in pretreated non-Hodgkin's lymphomas (Short report) 970
versus vindesine 815
- visual analogue scales
after discontinuation of hypnotics (Short report) 855
- vomiting
induced by low-dose cisplatin- or non-cisplatin-containing chemotherapy 505
- wait-and-see policy
in stage I₀ follicular lymphoma 713
- W**
- Waldenström's macroglobulinemia
purine analogs (Review) S6: 27
- whole abdominal radiation
of ovarian cancer 65
- Working Formulation
morphological classification (Review) S6: 3
REAL classification (Review) S6: 35
- X**
- xenografts
in mice 291

Index of authors Volume 7 (1996)

A

Aalders JG 511
 Aapro MS 553
 Aaronson NK 381
 Abad A 95
 Abigerges D 837
 Abrahamsen AF 257
 Abu Rabia A 751
 Achterrath W 55
 Airoma G 821
 Albertsson M 731
 Alexander E S4: 5
 Algeri R 747
 Alonso JL 643
 Amadori D 487
 Amadori S 933
 Ambros P 607
 Ambrosetti A 793
 Anagnostopoulos I S4: 61
 Andersen JS 347
 Anderson JR 151
 André T 173
 Andrei A 747
 Andrieu JM 525
 Andrizzi C 933
 Ang PT 71
 Angeletti CA 747
 Anselmo AP 1071
 Antoine E-C S2: 31
 Antón-Torres A 581
 Apolinario RM 625
 Aranda E 581
 Arbuck SG 567
 Ariad S 321
 Armand J-P 6, 837
 Armitage JO 151, S6: 1
 Armstrong AA S4: 5
 Arseniev L S2: 41
 Ascoli E 537
 Ashley SE 671
 Athanasiadis I 15
 Atsumi R 491
 Audhuy B 575
 Audisio E 919
 Avenin D 173
 Avvisati G 1071
 Azli N 165
 Azzouzi K 173

B

Bacchi M 65, 471
 Bacci G 864
 Bachmann P 637

Badwe RA 355
 Baert AL 871
 Baldini E 487, 747, 857
 Balzarotti M 970
 Bamberg M 755
 Bandieri E 619
 Bangerter M S4: 55
 Bapsy PP 424
 Barbarano L 537
 Barbareschi M 695
 Barbazza R 695
 Barbieri F 412
 Barneto I 581
 Bard JM 581
 Baroni CD 1071
 Barozzi P 619
 Barrington R 491
 Barth S S4: 135
 Batist G 1077
 Baumann I 1051
 Bayo R 719
 Becher R 55
 Bedikian A 827
 Benoy I 843
 Bensmaïne MA 1065
 Benvenuto F S2: 19
 Beretta K 471
 Bergerat J-P 575
 Bergman B 365
 Bergonzi C 537
 Bernhard J 426
 Bernier J 541
 Bernstein M 536
 Berthold F 183, 607
 Bertini M 919
 Bertino J S2: 53
 Bertoni F 1023
 Besa P 157
 Betticher DC 223, 793
 Bevilacqua P 695
 Bewermeier P 83
 Beyer J 31
 Bhansali MS 355
 Bhatt RG 355
 Bianco AR 821
 Bierman PJ 151, 265
 Binder C 129
 Binder L 129
 Binder T S4: 55
 Biron P 996, 967
 Bisagni G 99
 Bishop MR 151
 Bitton R 939

Blackburn N 208
 Blijham GH 879
 Bliss J 989
 Boaziz C 525
 Boccardo F 239
 Body JJ 643
 Boe J 257
 Boersma AWM 75
 Boesgaard M 687
 Bohlen H 397, S4: 45
 Bokemeyer C 31, 416, 755, 1015
 Bolhuis RLH 317
 Bonadonna G 221, 481, 970
 Bonazzi C 419
 Bonichon F 713
 Bonoldi E 695
 Boogaerts MA S2: 1
 Boomstra H 511
 Boracchi P 695
 Bordessoule D 966
 Borisch B 953
 Borsellino P 907
 Bosman FT 75
 Bosq J 925
 Bosshard G 1023
 Botto B 919
 Bougon N 165
 Bouleuc C 173
 Bovbjerg DH 977
 Boven E 35
 Boyle P 439
 Bradley B S2: 47
 Brandwein JM 1043
 Breu H 183
 Briccoli A 864
 Brienza S 95, 1065
 Broggini M 343
 Brown TD 347
 Bruera E 855
 Brugger W 871, S2: 1, 11
 Brugnatelli S 537
 Brunelli C 907
 Brunetti I 601
 Buckley CH 705
 Bullorsky E 719
 Burchill S 297
 Burger H 75
 Bürgi K 793
 Burns DJ 291
 Burris III HA 179, 347, 491
 Buser K 65
 Butow PN 189
 Buttitta F 695

- Buzaid AC 827
- C**
- Cabanillas F 157, 211, 1083
 Caffo O 695
 Caillet H 1065
 Cairncross G 205
 Caligara M 613
 Calvi R 919
 Cameron DA 409
 Campanacci 864
 Canellos GP S4: 91
 Canepa C 719
 Canevari S 227
 Carbone GMR 659
 Carde P 925
 Carella AM S2: 1, 19
 Carlier P S2: 19
 Carnino F 487
 Carrato A 581
 Carstairs K 1043
 Cartoni C 1071
 Cascini S 538
 Casella C 239
 Casper ES 347
 Cassidy J 208
 Castellani A 538
 Castiglione-Gertsch M 245, 471
 Catalano G 538
 Catapano CV 659
 Catimel G 837
 Cavalli F 7, 245, 471, 807, 1023
 Cavanna L 537
 Cavina R 640
 Ceresa E 1023
 Cerny T 793
 Cerottini J-C 339
 Cerutti I 719
 Cervantes A 581
 Chan WC S4: 41
 Chandrashekhar M 424
 Chang J 671, 756
 Chella A 747
 Cheson BD 767
 Chevallier B 165
 Childs AM 189
 Chimirri F S2: 19
 Chollet P 1065
 Christiansen H 183
 Cianci C 601
 Classen S 391
 Clavel M 837
 Coates AS 189, 245
 Cocconi G 99, 433
 Cognetti F 821, 867
 Coiffier B 966
 Colder CD 303
 Collins CD 705
- Collins DJ 47, 245
 Colombo N 419
 Colombo T 801
 Combaret V 607
 Connors TA 445
 Conte PF 487, 601, 747, 857, 978
 Conter V 725
 Cooper MR 939
 Cooper D 1029
 Cormio G 271
 Corrado C 719
 Cortés-Funes H 245, S2: 1, S2: 23
 Cosset JM 925
 Cox J 157
 Craze JL 89
 Cremin P 745
 Crescenti C S2: 19
 Crippa MC 347
 Crisi G 412
 Crombez R 277
 Crown J 405
 Crowther D 705
 Crump M 311, 1043
 Cucchi M 919
 Culine S 997
 Cummings J 291
 Cunningham D 47, 179, 277, 961
 Cure H 575, 1065
 Cvitkovic E 1065
 Cwikiel M 731
- D**
- D'Aprile M 821
 D'Incalci M 725, 801
 Dalesio O 139
 Dalla Palma P 695
 Daly PA 745
 Dannecker C 391
 Dau H S4: 35
 de Boer CJ 251
 de Bruijn HWA 511
 de Bruijn KM 505
 De Crescenzo A 919
 de Graeff A 867
 de Gramont A 95
 de la Chapelle A 883
 de Micheli R 487
 de Mulder PHM 277, 521, 867
 de Paoli A 537
 de Placido S 821
 de Pooter C 843
 de Rijke JM 677
 de Vries EGE 505, 511
 de Wit R 1080
 de Wynter E 1051, S2: 5
 Decaudin D 925
 Deerberg-Wittram J S4: 49
 Dejana A S2: 19
- del Valle ML 755
 Del Ferro E 538
 Delabie J S4: 41
 Delfini R 1071
 Deloche C 1065
 Demicheli R 640
 Dengra C 719
 Denning-Kendall P S2: 47
 Dent SF 561
 Depierre A 945
 Desai PB 355
 Devi L 424
 Dexter TM 1051
 Dhermain F 925
 Di Mola G 907
 Di Palma M 525
 Di Palma S 640
 Diaz-Rubio E 95, 581, 643
 Dictato M 277
 Diehl V 397, S4: 1, 45, 61, 95, 109, 135
 Diener P 65
 Dieras V 165
 Dingemans A-MC 625
 Dirix LY 843
 Dobson M 705
 Dolensky J 637
 Dombernowsky P 365, 687
 Dominici C 607
 Donaldson C S2: 47
 Donati D 864
 Dookeran KA 535
 Doval DC 424
 Dreef E 251
 Dreyfus B 575
 Drings P 139, 637
 Drinkard LC 314
 Droz JP 997
 Drumea K 536
 du Bois A 277
 Duclos B 575
 Dufour B 525
 Dufour P 575
 Dukoff R 103
 Duillemond-Westland AC 505
 Dumas F 575
 Dunn SM 189
 Duyster J S4: 19
- E**
- Eberhardt W 55
 Eckhardt JR 491
 Eckhardt SG 491
 Ecstein E 525
 Edington H 535
 Egger T 793
 Eggermont AMM 317
 Eghbali H 713
 Einsele H 416

- Eisenhauer E 205, 311, 561, 1077
 El-Attar I 751
 El-Said A 751
 Ellis PM 189
 Enander L-K 593
 Engeler V 65
 Engert A 397, S4: 1, 109, 135
 Erley C 416
 Errante D 233
 Erttmann R 183, 607
 Eskilsson J 731
 Esteso A 173
 Esteve J 607
 Etienne M-C 283
 Eton O 827
 Extra YM 837
 Eyal A 536
- F**
 Fainsinger RL 855
 Falcone A 601
 Falkson CI 465
 Falkson HC 465
 Farber C 1083
 Favrot MC 607
 Federico M 619
 Feine U 416
 Feldman L 719
 Fentiman IS 657
 Fernandes DJ 659
 Fernández I 719
 Fernández-Martos C 581
 Ferrari MG 619
 Ferrari S 864
 Fetscher S 871
 Fey MF 121, 471, 758, 766, 953, 1086
 Fibbe WE S2: 1, 15
 Fields S 491
 Figg WD 939
 Findlay MPN 47
 Fisher B 311, 1077
 Fisher RI S4: 131, S6: 35
 Flashove M S2: 53
 Flattery M 745
 Flens MJ 75
 Florio G S2: 19
 Follath F 1059
 Forbes JF 245
 Forfang K 257
 Fomi C 864
 Fomi M 65
 Fournier M 970
 Forsyth P 205
 Foss Abrahamsen A 145
 Fossella FV 59
 Fountzilas G 517
 François E 95
 Franklin J S4: 61
- Franzén L 587
 Frappaz D 607
 Fraschini F 99
 Frassoldati A 619
 Frassoni F S2: 19
 Freeman MB 151
 Freilone R 919
 Frickhofen N S4: 55
 Fukuoka M 815
 Fuller LM 157, 211
 Fumoleau P 165
 Furuse K 815
- G**
 Gaafar R 751
 Gabriele A 271, 861
 Gad El-Mawla N 751
 Gallamini A 919
 Gallardo H S2: 53
 Galligioni E 245
 Gallino A 1059
 Gallo C 821
 Gallotti P 487
 Gallucci M 907
 Gamba A 907
 Gamelin E 95
 Gamucci T 529
 Garcia-Boyoero R 322
 Garcia JJ 719
 Garcia-Conde J 581
 Gardin G 487
 Gardiner J 409
 Gasparini G 441, 695
 Gastiaburu J-J 95
 Gause A S4: 35
 Gebbia V 821
 Gehl J 687
 Gelber RD 245, 335
 Gennari A 857, 978
 Gentili D 725
 Gentilini P 487
 Ghio R 919
 Giaccone G 35, 139, 625, 637
 Giannopoulos A 644
 Gieser PW 1009
 Giordano M 537
 Girinsky T 925
 Girouard C 1043
 Gisselbrecht C 966
 Giulianotti PC 601
 Glimelius B 593
 Gnekow A 183
 Goedhals L 945
 Goey SH 317, 887
 Golman L 321
 Goldhirsch A 65, 213, 245, 471, 801, 807
 Goldstein D 1029
 Golomb HM 314
- Gonzalez Paz O 801
 Gore M 179, 297
 Grandi C 640
 Graziano F 538
 Green MR 347
 Gregory RK 671, 756
 Greiner R 65
 Greiner TC 265
 Gridelli C 821
 Griesshammer M S4: 55
 Griffin AM 189
 Grise P 525
 Griso L 919
 Grogan TM S6: 3
 Groisman GM 536
 Gruss H-J S4: 19
 Gudgeon A 245
 Guerci A 966
 Guex P 135, 645
 Guillot T 283
 Guzzo M 640
- H**
 Hafner M S4: 55
 Hagberg H 587
 Hagemeister FB 157, 1083
 Hager B 145
 Haier B 397
 Hain N 536
 Hamza M-R 751
 Hanauke AR 529
 Hannisdal E 145
 Hannoun L 173
 Hansen HH 119, 365
 Hansen M 365
 Hansmann M-L S4: 27, 61
 Haraf DJ 739, 913
 Harper P 961
 Harstrick A 31, 55, 1015
 Hartmann F S4: 143
 Hasenclever D S4: 95
 Hassan R 103
 Hauke RJ 265
 Haupt A 1015
 Hayat M 925
 Hayungs J 55
 Headlee D 939
 Hebart H 416
 Heesters MAAM 511
 Heimpel H S4: 55
 Heinz R 423
 Hejna M 973
 Helle P 139
 Heneka M 755
 Henriksson R 587
 Henry-Amar M S4: 115
 Herbrecht R 966
 Hero B 183

- Herrmann F 183, S4: 19
 Herrmann R 551
 Hess M 157
 Hiddemann W 129
 Higashi L 491
 Hirsch FR 365
 Hoekman K 35
 Hoem B 713
 Hoffman K 593
 Hoffman PC 314
 Hohenberger P 197
 Hollema H 511
 Holmberg L 655
 Holte H 145
 Hong WKi 59
 Honkoop AH 35
 Hopfinger G 423
 Hoppe RT S4: 99, S4: 105
 Horak ID 103
 Hornedo J S2: 23
 Horning SJ 115, S4: 105, S6: 21
 Horwich A 989
 Hoskins P 1077
 Hossfeld DK 83
 Houry S 173
 Howell A 773, 1051
 Hows J S2: 1, S2: 47
 Hoy J 1029
 Hsu Schmitz SF 793
 Hubens G 843
 Huber MH 59
 Hughes MJ 208
 Hummel M S4: 31
 Hünerbein M 197
 Husseini F 575
- K**
 Kalahannis N 644
 Kantarjian H S6: 27
 Kanz L 416, 755, 871, S2: 11
 Kanzler H S4: 27
 Kaplan EL 739
 Karabelis A 517
 Kaskas B 416
 Katagami N 815
 Kattis K 517
 Kawahara M 815
 Kaye SB 9, 208
 Keating A 1043
 Keating MJ S6: 27
 Kennealey G 179
 Kerbl R 607
 Kerbrat P 165
 Kerger J 867
 Kerneis Y 966
 Kerr DJ 208, 961
 Kessinger A 151
 Kester MGD 251
 Khaled HM 751
 Khayat D S2: 1, S2: 31
 Kiani A 871
 Kinuwaki E 815
 Kiowski W 1059
 Kirkpatrick A 139, 867
 Kiss A 543
 Klaassen U 55
 Klingebiel T 183
 Kluin-Nelemans JC 251
 Kluin PM 251
 Kohler D 939
 Köhrmann O 1015
 Köhrmann U 31
 Kok TC 533
 Kongerud J 257
 König M 416
 Koo WH 71
 Koppejan AG 677
 Kornek G 973
 Koscielny S 925
 Kosmidis P 517
 Koziner B 719
 Krakowski Y 165
 Kramar A 997
 Krauss SA 314
 Kristjansen PEG 365
 Krüger W 83
 Krzemieniecki K 977
 Kuba M 815
 Kube D 397
 Kubota K 815
 Kuhn JG 491
 Küpper M S4: 35
- Küppers R S4: 27
 Kusminsky G 719
 Kvaløy S 145
- L**
 La Vecchia C 497
 Labianca R 901
 Lachter J 536
 Lambert HE 361
 Lampe C 755
 Lampert F 183
 Lan J 529
 Langdon SP 291
 Lange C 1051
 Lange W 871
 Langholm R 145
 Langnas AN 265
 Larregain D 525
 Lassen U 365
 Lastiri F 719
 Latreille J 311
 Leach MO 47
 Lederlin P 966
 Lee JS 59
 Lee LE 409
 Lefebvre JL 867
 Legha SS 827
 Lehner M 529
 Lencioni M 601
 Lentz M-A 637
 Leonard JP S2: 53
 Leonard RCF 291, 409
 Leonard T 409
 Leonardi V 821
 Lerma E S2: 19
 Leszler A 575
 Levi F 497
 Levis A 919
 Lewis C 1029
 Leyvraz S 65
 Licitira L 640
 Liénard D 339
 Ligi M 538
 Liliemark J 373, 1037
 Linch DC S2: 1, S2: 9
 Lindtner J 245
 Link H S2: 1, S2: 41
 Linné T 593
 Lippman SM 59
 Liasoni A 271, 861
 Loeffler M S4: 95
 Loftin U S4: 35
 Löhner T 471
 Lomberg H 587
 Longo DL S4: 85
 López JA 643
 Lorigan PC 631
 Losa G 861

- Losch M 55
 Lotz JP 173
 Lotze MT 535
 Lucas V 525
 Luft T 1051
 Lund MB 257
 Luporini G 901
 Luppi G 412
 Luppi M 619
 Lush RM 939
 Lusignani M 907

M
 Macdonald D 205
 Machover D 95
 Mackay J 291, 409
 Magrath I 751
 Manegold Ch 637
 Maneo A 271, 419, 801
 Manfrini M 864
 Mangioni C 419, 861
 Mann J 607
 Marafioti T S4: 31, S4: 61
 Marasca R 619
 Marchal G 871
 Marchetti A 695
 Margalaška K 977
 Marini G 245, 807
 Mark J S2: 15
 Martin C 575
 Martin M 643, 843
 Martinez Rolón J 719
 Marty M 95, 837
 Marx D 129
 Marzola M 419
 Masera G 725, 1005
 Massara G 919
 Massuti T 581
 Masters GA 314
 Masuo K 491
 Mathieu P 607
 Mauch PM S4: 79
 Maugard-Louboutin C 165
 Maurizi Enrici R 1071
 Mayer R 416
 Mayeur D 525
 McCann SR 745
 McClary KA 977
 McGregor K 208
 McLaughlin P 157, 211, 1083
 McQuade B 277, 945
 McRae J 277, 945
 McVie G 139
 Mead G 849
 Meerpohl HG 416
 Meloni G 933
 Ménard S 227
 Mercadante S 613

 Mercuri M 864
 Mermershtain W 321
 Meropol NJ 179
 Merran S 525
 Mertelsmann R 871
 Metzger G 95
 Metzner B 31
 Michail P 644
 Michelotti A 857
 Milano G 283
 Miller WR 291
 Milliken S 1029
 Milone G 719
 Milone J 719
 Mirimanoff RO 870
 Misra S 424
 Misset J-L. 165
 Moleti ML 933
 Molinari R 640
 Montgomery GH 977
 Monzeglio C 487
 Moore MAS S2: 1, S2: 53
 Moore MJ 347
 Morgenstern GR 631
 Morselli M 619
 Mosca F 601
 Mross K 83
 Müller-Wehrich St 183
 Munck JN 925
 Murray S 245
 Myers J 1083
 Mylonakis N 517

N
 N'Daw D 95
 Nagel S 953
 Nakai Y 815
 Natali M 821
 Negoro S 815
 Neijt JP 988
 Nelstrop AE 361
 Newell M 1029
 Newman RA 59
 Nicol A S2: 47
 Nieda M S2: 47
 Niedobitek G S4: 11
 Nieto Y 643
 Niitani H 815
 Nikou G 644
 Nome O 145, 257
 Nooter K 75
 Nooy M 505
 Nyman J 587
 Nyth AL 587

O
 O'Brien S S6: 27
 O'Reilly E 405

 Öberg K 453
 Oberlin O S4: 73
 Oberling F 575
 Oechslin E 1059
 Oguma T 491
 Olivares R 575
 Oliver I 961
 Olivier J-P 575
 Olver I 945
 Onetto N 1077
 Oostrum RG 75
 Oriandoni D 725
 Orsini E 933
 Orsucci L 919
 Osakam R 317
 Österlind K 365
 Ottensmeier C 849

P
 Paaske T 687
 Paganini O 213
 Palazzolo G 821
 Palmeri S 821
 Pancera G 901
 Pantalony D 1043
 Papachristodoulou A 644
 Papadopoulos N 827
 Papargyriou J 644
 Parczewska J 977
 Paridjans R 277
 Parker L 607
 Parma G 419, 861
 Paska W 945
 Pate O 1083
 Patil PK 355
 Pavlidis N 517, 529
 Pavlovitch JM 525
 Pavlovsky S 719
 Pawinski A 637
 Pawlicki M 977
 Pazdur R 179
 Pedrinis E 1023
 Pelosio P 695
 Pepe R 821
 Perez-Manga G 961
 Perrone F 821
 Perrotta A 239
 Pesce G 807
 Petruini M 537
 Petruzelka L 637
 Pettit MC 933
 Pfanner E 601
 Pfeilstöcker M 423
 Pfister Ch 99
 Pfreundschuh M S4: 143, S4: 35
 Philip T 607
 Picci P 864
 Piccinini L 412

- Pike J 1077
 Pinedo HM 35
 Pinto RM 933
 Piro LD S6: 41
 Pittelli MR 419
 Pittermann E 423
 Pittman K 297
 Plager C 827
 Planting AST 139, 755, 1080
 Pluda JM 939
 Podestà M S2: 19
 Polyzos A 644
 Portenoy RK 347
 Portlock C 1083
 Possinger K 391
 Postumus PE 303, 625
 Powell J 607
 Powles TJ 671, 756
 Pras E 511
 Prencipe E S2: 19
 Prendiville J 705
 Presta M 441
 Prevost G 575
 Price KN 245
 Prince HM 1043
 Pritchard J 89
 Proia A 1071
 Pronzato P 487
 Pujaide-Lauraine E 525
 Pupa SM 227
- R**
 Raderer M 973
 Radford JA 705, 793
 Rajewsky K S4: 27
 Randimbison L 497
 Ranson M 705
 Rao CR 424
 Räth U 961, 1015
 Raynaud F 47
 Recant W 739
 Reed E 939
 Regazzo C 907
 Regazzoni S 807
 Reifke J 83
 Renner C S4: 143
 Renninson J 705
 Resegotti L 919
 Reske SN S4: 55
 Reuß K S4: 109
 Reyes F 966
 Ricardi U 919
 Riccardi A 537
 Ricci S 601
 Richaud P 713
 Rifkin RM 265
 Rinaldi D 491
 Ring S 827
- Ripamonti C 855
 Ritchie AA 291
 Riva A 165
 Rizzari C 725
 Robinson A 719
 Roche H 165
 Rodenhuis S 104
 Rodriguez G 491
 Rodriguez MA 157
 Roggero E 787, 1023
 Romaguera J 157
 Romero P 339
 Rosenberg SA 555, S4: 105
 Rosenstein DL 103
 Rossi A 821
 Rosso R 487
 Rota Scalabrinii D 919
 Rota SM 271
 Rothenberg ML 347, 491
 Rubagotti A 239, 487
 Rubiales AS 755
 Rudenstam C-M 245
 Rüegg C 654
 Rufener B 793
 Rüffer J-U S4: 127
 Russo A 821
 Rustin GJS 361
 Rüther U 31
- S**
 Sørensen JB 119
 Sadelain M S2: 53
 Sahin U S4: 143
 Sahmoud T 867
 Sakuma A 815
 Saletti P 213
 Salles G 993
 Salvadori B 857, 978
 Salvi F 919
 Samanta E 517
 Samsonov ME 535
 Samuels BL 314
 Sanna P 1023
 Santoro A 970
 Santosuosso A 907
 Sanz GF 322
 Sanz MA 322
 Sapio M 613
 Saporito G 719
 Sarris A 1083
 Sartor O 939
 Sastre J 95
 Savarino M 619
 Sawka C 205
 Scaglione F 99
 Scarffe JH 631
 Schabot M 755
 Schauer A 129
- Scheding S S2: 11
 Scheithauer W 973
 Schellong G S4: 67
 Scheper RJ 75, 625
 Schijf CPT 521
 Schilf A 95
 Schilling F 607
 Schlegelberger B S4: 49
 Schlögl E 423
 Schmoll H-J 31, 1015
 Schnaars Y 637
 Schneider J 1059
 Schnell R S4: 135
 Schoeller T 855
 Schöffski P 1015
 Schornagel J 867
 Schouten HC 677
 Schouten LJ 677
 Schuurings E 251
 Scinto AF 821
 Scott G 1043
 Sebban C 966
 Secondo V 919
 See J 173
 Seeber S 55
 Seitz J-F 95, 945, 961
 Selby P 277, 297
 Sellström H 593
 Senn H-J 245, 471
 Serretta R 613
 Sessa C 8, 65, 213, 645, 801
 Sextro M S4: 61
 Seymour JF 157, 211
 Seymour L 179
 Shepherd FA 311
 Shuster JJ 1009
 Siderov J 41
 Sieber M S4: 127
 Siegenbeek van Heukelom L 505
 Sigsgaard TC 365
 Sikora SS 535
 Silingardi V 412
 Silvano G 747
 Simes J 41
 Singh R 671, 671
 Sjödén P-O 593
 Skacel Z 637
 Skarlos D 517
 Smetzer L 491
 Smir BN 265
 Smith B 297
 Smith IE 179, 771
 Smyth JF 211, 277, 529
 Soracco M S2: 19
 Sorbe B 587
 Soubeyran P 713
 Soukop M 208
 Southgate J 297

- Splinter TAW 533
 Sprangers MAG 381
 Srinivas V 424
 Stahl M 55
 Stavenow L 731
 Stein H S4: 31, S4: 61
 Stein ME 536
 Sternberg CN 878
 Stewart AK 277, 1043
 Stewart DJ 205, 311, 945
 Stiefel F 135, 645
 Stockman P 291
 Stormiolo A-M 347
 Stoter G 75, 317, 887, 1080
 Stuart G 1077
 Sudo K 491
 Sutcliffe S 1043
 Sutton DMC 1043
 Svensson C 593, 961
 Swan F 157
 Sweeney PJ 739
 Swenerton K 1077
 Swindell R 705, 1051
 Sylvester R 324
 Szabó BG 511
 Szendro G 321
 Sznol M 667
- T**
 Takada Y 815
 Tamburini M 907
 Tarassoff PG 347
 Tattersall MHN 189, 245
 Te VC 497
 Te Velde A 381, 529
 ten Bokkel Huinink WW 104
 Tesch H 397, S4: 109
 Testa NG 1051, S2: 1, S2: 5
 Thill L 575
 Thomson B 1029
 Thürlmann B 471
 Tibaldi C 747, 857
 Tidy VA 671
 Tilly H 966
 Tirelli U 233
 Tischler J 1015
 Tobler A 121, 953
 Tognoni A 857, 978
 Tomiak E 311
 Tondini C 970
 Torelli G 619
 Toscani F 907
 Toskas A 644
 Tournani JM 525
 Treleaven JG 671
 Trojani M 713
 Trümper L S4: 35
 Trunet PF 99
- Tsang R 1043
 Tschuemperlin B 725
 Turina M 1059
 Tuxen MK 361
- U**
 Ucci G 537
 Uhr MR 646, 980
 Untereiner M 525
- V**
 Vaccher E 233
 Vaidya JS 355
 Valagussa P 221, 481
 Valbonesi M S2: 19
 Valsecchi MG 1005
 van Ark-Otte J 625
 van Cutsem E 871, 961
 van den Brandt PA 677
 van der Burg MEL 1080
 van der Gaast A 75, 533
 van der Graaf WTA 505
 van der Heul C 505
 van der Linden GHM 505
 van der Valk P 625
 van Glabbeke M 637
 van Groeningen CJ 35
 van Hoe L 871
 van Hoeff MEHM 1051
 van Hoesel QGCM 521
 van Krieken JHJM 251
 van Oosterom AT 843
 van Straelen D 277
 van Wingerden KE 75
 van Zandwijk N 637
 Vanhoefer U 55
 Vannucci L 601
 Varette C 525
 Vassallo F S2: 19
 Veltre E 821
 Venturini M 487
 Verbeek W 31
 Verderio P 695
 Vergote I 871
 Verhagen CAHHVM 521
 Vermeulen PB 843
 Vermorken JB 35, 867
 Verweij J 277, 333, 529, 867, 887, 1080
 Vignetti M 933
 Vignoud J 95
 Vitolo U 919
 Vittrup Jensen B 687
 Vogel W S2: 11
 Vokes EE 15, 314, 739, 913
 von Bonin F S4: 35
 von Hoff DD 347, 491
 von Rohr A 793, 953
 Vorbeck F 973
- Vose JM 151, 265, S6: 13
 Vuillemin E 525
- W**
 Wagstaff J 35
 Wainman N 205
 Waldner R 423
 Watts MJ S2: 9
 Weaver A 705, S2: 5
 Weber-Matthiesen K S4: 49
 Weichselbaum RR 913
 Weinel P 183
 Weinlaender G 973
 Weiss G 491
 Weißbach L 31, 1015
 Wester M 59
 Westermann AM 104
 Westermann F 397
 Wiggers Th 317
 Wildiers J 867
 Wilke H 55
 Wilkinson JR 945
 Willems PHB 511
 Willemsen R S2: 15
 Wils JA 211, 505
 Wolf J S4: 45
 Woodings PL 631
 Wrigley E 705
 Wymenga ANM 505
- Y**
 Yamori S 815
 Ychou M 95
 Yosef H 208
 Younes A 1083
- Z**
 Zalcberg JR 41, 179, 961
 Zambetti M 481
 Zander A 83
 Zanetta G 271, 861
 Zanoni A 864
 Zatloukal P 637
 Ziemann K S4: 31
 Zijlmans JM S2: 15
 Zoboli A 412
 Zucca E 787, 793, 1023
 Zucchetti M 725, 801
 Zuehsdorf M 397
 Zwierzina H 667

